<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="pcmr13210" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pigment Cell Melanoma Res</journal-id><journal-id journal-id-type="iso-abbrev">Pigment Cell Melanoma Res</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1755-148X</journal-id><journal-id journal-id-type="publisher-id">PCMR</journal-id><journal-title-group><journal-title>Pigment Cell &#x00026; Melanoma Research</journal-title></journal-title-group><issn pub-type="ppub">1755-1471</issn><issn pub-type="epub">1755-148X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39609109</article-id><article-id pub-id-type="pmc">PMC11681848</article-id>
<article-id pub-id-type="doi">10.1111/pcmr.13210</article-id><article-id pub-id-type="publisher-id">PCMR13210</article-id><article-id pub-id-type="other">24-RE-130.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer</article-title></title-group><contrib-group><contrib id="pcmr13210-cr-0001" contrib-type="author"><name><surname>Broseghini</surname><given-names>Elisabetta</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7401-9842</contrib-id><xref rid="pcmr13210-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr13210-cr-0002" contrib-type="author" corresp="yes"><name><surname>Venturi</surname><given-names>Federico</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5053-4172</contrib-id><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>federico.venturi@hotmail.it</email></address></contrib><contrib id="pcmr13210-cr-0003" contrib-type="author"><name><surname>Veronesi</surname><given-names>Giulia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6595-7776</contrib-id><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="pcmr13210-cr-0004" contrib-type="author"><name><surname>Scotti</surname><given-names>Biagio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7461-1726</contrib-id><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="pcmr13210-cr-0005" contrib-type="author"><name><surname>Migliori</surname><given-names>Marina</given-names></name><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="pcmr13210-cr-0006" contrib-type="author"><name><surname>Marini</surname><given-names>Desy</given-names></name><xref rid="pcmr13210-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="pcmr13210-cr-0007" contrib-type="author"><name><surname>Ricci</surname><given-names>Claudio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6638-4479</contrib-id><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="pcmr13210-cr-0008" contrib-type="author"><name><surname>Casadei</surname><given-names>Riccardo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9486-8190</contrib-id><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="pcmr13210-cr-0009" contrib-type="author"><name><surname>Ferracin</surname><given-names>Manuela</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1595-6887</contrib-id><xref rid="pcmr13210-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr13210-cr-0010" contrib-type="author"><name><surname>Dika</surname><given-names>Emi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3186-2861</contrib-id><xref rid="pcmr13210-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="pcmr13210-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="pcmr13210-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>IRCCS Azienda Ospedaliero&#x02010;Universitaria di Bologna</institution>
<city>Bologna</city>
<country country="IT">Italy</country>
</aff><aff id="pcmr13210-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medical and Surgical Sciences (DIMEC)</named-content>
<institution>University of Bologna</institution>
<city>Bologna</city>
<country country="IT">Italy</country>
</aff><aff id="pcmr13210-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Oncologic Dermatology Unit</named-content>
<institution>IRCCS Azienda Ospedaliero&#x02010;Universitaria di Bologna</institution>
<city>Bologna</city>
<country country="IT">Italy</country>
</aff><aff id="pcmr13210-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Internal Medicine Unit</named-content>
<institution>IRCCS Azienda Ospedaliero&#x02010;Universitaria di Bologna</institution>
<city>Bologna</city>
<country country="IT">Italy</country>
</aff><aff id="pcmr13210-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Pancreas and Endocrine Surgery Unit</named-content>
<institution>IRCCS Azienda Ospedaliero&#x02010;Universitaria di Bologna</institution>
<city>Bologna</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Federico Venturi (<email>federico.venturi@hotmail.it</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><volume>38</volume><issue seq="70">1</issue><issue-id pub-id-type="doi">10.1111/pcmr.v38.1</issue-id><elocation-id>e13210</elocation-id><history>
<date date-type="rev-recd"><day>01</day><month>10</month><year>2024</year></date>
<date date-type="received"><day>26</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>15</day><month>10</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2025 John Wiley & Sons A/S--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Pigment Cell &#x00026; Melanoma Research</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PCMR-38-0.pdf"/><abstract><title>ABSTRACT</title><p>Cutaneous melanoma (CM) and pancreatic cancer are aggressive tumors whose incidences are rapidly increasing in the last years. This review aims to provide a complete and update description about mutational landscape in CM and pancreatic cancer, focusing on similarities of these two apparently so different tumors in terms of site, type of cell involved, and embryonic origin. The familial forms of CM and pancreatic cancers are often characterized by a common mutated gene, namely <italic toggle="no">CDKN2A</italic>. In fact, a germline mutation in <italic toggle="no">CDKN2A</italic> gene can be responsible for the development of the familial atypical multiple mole and melanoma syndrome (FAMMM), which is characterized by melanomas and pancreatic cancer development. Sporadic melanoma and pancreatic cancer showed different key&#x02010;driven genes. The open&#x02010;access resource cBioPortal has been explored to deepen and investigate the common mutational landscape of these two tumors. We investigated the common mutated genes found in both melanoma and pancreatic cancer with a frequency of at least 5% of tested patients and copy number alterations with a frequency of at least of 3%. Data showed that 18 mutated genes and 3 copy number alterations are present in both melanoma and pancreatic cancers types. Since we found two patients that developed both melanoma and pancreatic cancer, we compared mutation landscape between the two tumors and identified a pathogenic variant in <italic toggle="no">BRCA2</italic> gene. This review gives valuable insights into the genetic underpinnings of melanoma and pancreatic cancer, urging the continued exploration and research of new genetic biomarkers able to identify patients and families at high risk of developing both cancers and to address to screening and to an effective clinical management of the patient.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pcmr13210-kwd-0001">cutaneous melanoma</kwd><kwd id="pcmr13210-kwd-0002">genomics</kwd><kwd id="pcmr13210-kwd-0003">germline mutations</kwd><kwd id="pcmr13210-kwd-0004">pancreatic cancer</kwd></kwd-group><counts><fig-count count="0"/><table-count count="7"/><page-count count="22"/><word-count count="13600"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="pcmr13210-ntgp-0001"><fn fn-type="funding" id="pcmr13210-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn fn-type="equal" id="pcmr13210-note-0002"><p>Elisabetta Broseghini and Federico Venturi contributed equally to this work and share first authorship.</p></fn></fn-group></notes></front><body id="pcmr13210-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="pcmr13210-blkfxd-1101"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="pcmr13210-list-1101"><list-item id="pcmr13210-li-1101"><p>Familial melanoma and pancreatic cancer can be associated with an inheritance pattern of germline mutations in predisposing genes.</p></list-item><list-item id="pcmr13210-li-1102"><p>This study contributes valuable insights to identify patients at high risk of developing both cancers and to guide clinicians in performing appropriate genetic testing and surveillance program.</p></list-item></list>
</p></boxed-text>
</p><sec id="pcmr13210-sec-0001"><label>1</label><title>Introduction</title><p>It is now recognized that familial melanoma and pancreatic cancer can be linked to inherited germline mutations in predisposing genes. This review gives valuable insights into the genetic underpinnings of melanoma and pancreatic cancer, urging the continued exploration and research of new genetic biomarkers able to identify patients and families at high risk of developing both cancers and to address such patients to screening programs for early identification of such cancers and to an effective clinical management of the patient to paving the way for possible future treatments based on gene&#x02010;targeted therapies (Ribero et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0111" ref-type="bibr">2016</xref>; Aung et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0005" ref-type="bibr">2018</xref>). To deepen and investigate the genetic landscape of these two cancers, an open&#x02010;access and open&#x02010;source resource, namely cBioPortal for Cancer Genomics, has been used to explore multidimensional cancer genomics datasets.</p></sec><sec id="pcmr13210-sec-0002"><label>2</label><title>Germline Mutations in Cutaneous Melanoma and Pancreatic cancer</title><p>Cutaneous melanoma (CM) is a malignant tumor that arises from the transformation of pigment&#x02010;producing cells known as melanocytes. CM incidence has increased during the past several decades and, although CM accounts for 3%&#x02013;5% of all skin cancers, it determines approximately 65% of all skin cancer deaths (Gershenwald and Scolyer&#x000a0;<xref rid="pcmr13210-bib-0045" ref-type="bibr">2018</xref>). The etiology of CM has been attributed mainly to environmental factors such as ultraviolet (UV) exposure. Other risk factors include patient&#x02010;related parameters such as fair phototypes and multiple dysplastic nevi. Genetic factors are less frequent; however, a family history of CM poses the highest risk for the development of melanoma (Dika, Broseghini, et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0030" ref-type="bibr">2021</xref>).</p><p>Around 7%&#x02013;15% of CM cases occur in patients with a family history of CM; however, this does not automatically indicate that a single genetic mutation is being transmitted in those kindreds. In fact, the majority of family history of melanoma are due to sporadic cases related to shared UV exposures experiences, geographic location, and susceptible skin types. Only about 10% of patients with family history are classified as hereditary melanoma. Patients with a genetic predisposition often showed early onset and multiple primary melanomas (MPM) (Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>). MPM refers to a patient that has developed at least two primary CMs in its lifetime. The highest risk to develop another melanoma is in the first year following the diagnosis of the primary melanoma, but the risk remains increased for at least 20&#x02009;years (Dika, Broseghini, et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0030" ref-type="bibr">2021</xref>; Dika, Patrizi, et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0031" ref-type="bibr">2021</xref>; Zocchi et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0155" ref-type="bibr">2021</xref>; Lambertini et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0077" ref-type="bibr">2023</xref>).</p><p>Several genes have been identified as involved to melanoma predisposition, some of them are still with unknown clinical relevance (Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>; Toussi et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>). The most frequent germline mutations responsible for the development of melanoma are reported in Table&#x000a0;<xref rid="pcmr13210-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="pcmr13210-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Germline mutation genes associated with melanoma.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description&#x02014;gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Protein</th><th align="center" valign="bottom" rowspan="1" colspan="1">Specific function</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effect of mutations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Clinical phenotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">Prevalence of mutations</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="2" valign="top" colspan="1">CDKN2A</td><td align="center" rowspan="2" valign="top" colspan="1">Cyclin dependent kinase inhibitor 2A</td><td align="center" valign="top" rowspan="1" colspan="1">p<sup>16INK4a</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibition of CDK4 and phosphorylation of RB</td><td align="center" valign="top" rowspan="1" colspan="1">Loss&#x02010;of&#x02010;function, cell cycle progression</td><td align="center" rowspan="2" valign="top" colspan="1">Superficial spreading melanoma. Pigmentation, pagetoid scatter, and spindle cell morphology in vertical growth phase</td><td align="center" valign="top" rowspan="1" colspan="1">20%&#x02013;40% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Rossi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0118" ref-type="bibr">2019</xref>)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">p<sup>14ARF</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibition of HDM2 and ubiquitination of p53</td><td align="center" valign="top" rowspan="1" colspan="1">Loss&#x02010;of&#x02010;function, cell cycle progression</td><td align="center" valign="top" rowspan="1" colspan="1">~1% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Rossi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0118" ref-type="bibr">2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDK4</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin&#x02010;dependent kinase 4</td><td align="center" valign="top" rowspan="1" colspan="1">CDK4</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibition of p16 tumor suppressor leading to phosphorylation of RB and cell cycle progression</td><td align="center" valign="top" rowspan="1" colspan="1">Alteration in binding domain, leading to reduced p16<sup>INK4A</sup> inhibition and, to cell cycle progression</td><td align="center" valign="top" rowspan="1" colspan="1">Superficial spreading melanoma. Pigmentation and pagetoid scatter</td><td align="center" valign="top" rowspan="1" colspan="1">0.68%&#x02013;1.4% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Potrony et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0104" ref-type="bibr">2015</xref>); Harland et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0052" ref-type="bibr">2016</xref>); Puntervoll et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0106" ref-type="bibr">2013</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BAP1</td><td align="center" valign="top" rowspan="1" colspan="1">BRCA1 associated protein 1</td><td align="center" valign="top" rowspan="1" colspan="1">BAP1</td><td align="center" valign="top" rowspan="1" colspan="1">Deubiquitinating enzyme, BRCA1 binding partner Implicated in chromatin modulation, transcriptional regulation, and DNA damage repair</td><td align="center" valign="top" rowspan="1" colspan="1">Loss&#x02010;of&#x02010;function, production of an altered protein that cannot function normally and may be broken down prematurely</td><td align="center" valign="top" rowspan="1" colspan="1">BAP1&#x02010;inactivated nevi:
<list list-type="bullet" id="pcmr13210-list-0001"><list-item id="pcmr13210-li-0001"><p>Exclusively or predominantly intradermal</p></list-item><list-item id="pcmr13210-li-0002"><p>Associated common nevus component often present (a combined nevus)</p></list-item><list-item id="pcmr13210-li-0003"><p>Epithelioid melanocytes with round to oval vesicular nuclei and abundant amphophilic cytoplasm</p></list-item><list-item id="pcmr13210-li-0004"><p>May show smaller epithelioid cells without abundant eosinophilic cytoplasm</p></list-item><list-item id="pcmr13210-li-0005"><p>May show rhabdoid features</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;1% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Potrony et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0104" ref-type="bibr">2015</xref>); Aoude, Wadt, et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0004" ref-type="bibr">2015</xref>); Zhang et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0152" ref-type="bibr">2019</xref>); Kwon, Lee, and Lee&#x000a0;(<xref rid="pcmr13210-bib-0075" ref-type="bibr">2023</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">POT1</td><td align="center" valign="top" rowspan="1" colspan="1">Protection of telomeres 1</td><td align="center" valign="top" rowspan="1" colspan="1">POT1</td><td align="center" valign="top" rowspan="1" colspan="1">Constituent of shelterin complex that regulates telomere processing and stability</td><td align="center" valign="top" rowspan="1" colspan="1">Lead to longer telomeres that predispose individuals to cancer</td><td align="center" valign="top" rowspan="1" colspan="1">Superficial spreading melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">0.48%&#x02013;1.7% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Potrony et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0104" ref-type="bibr">2015</xref>); Robles&#x02010;Espinoza et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0116" ref-type="bibr">2014</xref>); Zade and Khattar&#x000a0;(<xref rid="pcmr13210-bib-0151" ref-type="bibr">2023</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACD</td><td align="center" valign="top" rowspan="1" colspan="1">ACD shelterin complex subunit and telomerase recruitment factor</td><td align="center" valign="top" rowspan="1" colspan="1">ACD</td><td align="center" valign="top" rowspan="1" colspan="1">Constituent of shelterin complex that regulates telomere processing and stability</td><td align="center" valign="top" rowspan="1" colspan="1">Lead to longer telomeres that predispose individuals to cancer</td><td align="center" valign="top" rowspan="1" colspan="1">Superficial spreading melanoma, and lentigo maligna melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;1% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Potrony et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0104" ref-type="bibr">2015</xref>); Aoude, Wadt, et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0004" ref-type="bibr">2015</xref>); Aoude, Pritchard, et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0003" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TERT</td><td align="center" valign="top" rowspan="1" colspan="1">Telomerase reverse transcriptase</td><td align="center" valign="top" rowspan="1" colspan="1">Catalytic subunit of telomerase</td><td align="center" valign="top" rowspan="1" colspan="1">Telomerase reverse transcriptase, a component of telomerase. Normally repressed in postnatal somatic cells leading to shortening of telomeres</td><td align="center" valign="top" rowspan="1" colspan="1">Lead to longer telomeres that predispose individuals to cancer</td><td align="center" valign="top" rowspan="1" colspan="1">Nodular and superficial spreading melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">0.04%&#x02013;0.7% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Potrony et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0104" ref-type="bibr">2015</xref>); Harland et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0052" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TERF21P</td><td align="center" valign="top" rowspan="1" colspan="1">TERF2 interacting protein</td><td align="center" valign="top" rowspan="1" colspan="1">TERF21P</td><td align="center" valign="top" rowspan="1" colspan="1">Constituent of shelterin complex that regulates telomere processing and stability</td><td align="center" valign="top" rowspan="1" colspan="1">Lead to longer telomeres that predispose individuals to cancer</td><td align="center" valign="top" rowspan="1" colspan="1">Superficial spreading melanoma, and lentigo maligna melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;1% of melanoma&#x02010;prone families</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Potrony et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0104" ref-type="bibr">2015</xref>); Aoude, Wadt, et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0004" ref-type="bibr">2015</xref>); Aoude, Pritchard, et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0003" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MITF</td><td align="center" valign="top" rowspan="1" colspan="1">Melanocyte inducing transcription factor</td><td align="center" valign="top" rowspan="1" colspan="1">MITF</td><td align="center" valign="top" rowspan="1" colspan="1">A melanocytic lineage&#x02010;specific transcription factor, regulating differentiation, proliferation and survival of melanocytes</td><td align="center" valign="top" rowspan="1" colspan="1">Become a lineage&#x02010;survival oncogene</td><td align="center" valign="top" rowspan="1" colspan="1">Amelanotic. Thicker tumors (in some populations). Nodular melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">1.6%&#x02013;2.8% of melanoma patients</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Yokoyama et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0150" ref-type="bibr">2011</xref>); Bertolotto et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0009" ref-type="bibr">2011</xref>); Ciccarese et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0018" ref-type="bibr">2020</xref>); Garraway and Sellers&#x000a0;(<xref rid="pcmr13210-bib-0043" ref-type="bibr">2006</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MC1R</td><td align="center" valign="top" rowspan="1" colspan="1">Melanocortin&#x02010;1 receptor</td><td align="center" valign="top" rowspan="1" colspan="1">MC1R</td><td align="center" valign="top" rowspan="1" colspan="1">G protein coupled receptor for melanocyte&#x02010;stimulating hormone. Controls melanogenesis, and skin and hair color</td><td align="center" valign="top" rowspan="1" colspan="1">Loss&#x02010;of&#x02010;function, decreased eumelanin synthesis leading to fair skin and an increased sensitivity to UV exposure</td><td align="center" valign="top" rowspan="1" colspan="1">Anatomic site (arms; in carriers of more than one high&#x02010;risk variant)</td><td align="center" valign="top" rowspan="1" colspan="1">61%&#x02013;66% of melanoma patients (at least one main MC1R variants)</td><td align="center" valign="top" rowspan="1" colspan="1">Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>); Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>); Williams et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0143" ref-type="bibr">2011</xref>); Wolf Horrell, Boulanger, and D'Orazio&#x000a0;(<xref rid="pcmr13210-bib-0145" ref-type="bibr">2016</xref>)</td></tr></tbody></table><table-wrap-foot id="pcmr13210-ntgp-0002"><fn id="pcmr13210-note-0003"><p>
<italic toggle="yes">Note:</italic> Table was modified from Ribeiro Moura Brasil Arnaut et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0109" ref-type="bibr">2021</xref>) and Toussi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>).</p></fn></table-wrap-foot></table-wrap><p>More than 20% of familial CM cases are caused by a mutation in a high&#x02010;risk tumor predisposition gene, namely cyclin&#x02010;dependent kinase inhibitor 2A (<italic toggle="yes">CDKN2A</italic>). Germline mutations in <italic toggle="yes">CDKN2A</italic> increase the risk of melanoma by 65&#x02010;fold. In addition, the germline mutations in <italic toggle="yes">CDKN2A</italic> are present in 8%&#x02013;15% of patients diagnosed with MPM without familial history and up to 40% in patients with familial melanoma (Helgadottir et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0056" ref-type="bibr">2017</xref>). Interestingly, the probability to found <italic toggle="yes">CDKN2A</italic> mutations is about 1% in sporadic melanoma patients without personal and/or familial history of melanoma (Harland et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0051" ref-type="bibr">2014</xref>).</p><p>Germline mutations in <italic toggle="yes">CDKN2A</italic> gene can be responsible for the development of a syndrome characterized by multiple clinically atypical nevi, melanomas and, in a subset of patients, pancreatic cancer. This melanoma&#x02010;related syndrome was first described by Lynch and Krush&#x000a0;(<xref rid="pcmr13210-bib-0088" ref-type="bibr">1968</xref>) as familial atypical multiple mole and melanoma syndrome (FAMMM) and, second, by Clark Jr. et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0020" ref-type="bibr">1978</xref>) as B&#x02010;K mole syndrome or dysplastic nevus syndrome.</p><p>The connection between FAMMM and pancreatic cancer has been widely studied (Goldstein et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0047" ref-type="bibr">2006</xref>). In FAMMM patients, there is an estimated risk to develop pancreatic cancer 13&#x02013;22 times higher than the risk in the average population, and the risk increases to more of 40&#x02010;fold in <italic toggle="yes">CDKN2A</italic>&#x02010;mutant FAMMM patients (Lynch et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0087" ref-type="bibr">2008</xref>; de Snoo et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0029" ref-type="bibr">2008</xref>). In melanoma prone families, pancreatic cancer was observed in 28% of <italic toggle="yes">CDKN2A</italic>&#x02010;mutant kindreds compared to only 6% of <italic toggle="yes">CDKN2A</italic>&#x02010;wild&#x02010;type kindreds. Moreover, 74% of families with pancreatic cancer harbored a <italic toggle="yes">CDKN2A</italic> mutation compared to 33% of those families with only melanoma (Goldstein et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0047" ref-type="bibr">2006</xref>). The penetrance for pancreatic cancer has been estimated as 17% in <italic toggle="yes">CDKN2A</italic> mutation carriers by 75&#x02009;years of age (Vasen et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0136" ref-type="bibr">2000</xref>).</p><p>Studies have shown the presence of the inactivate protein product of <italic toggle="yes">CDKN2A</italic> gene, namely p<sup>16INK4a</sup>, in 95% of sporadic pancreatic cancers; however, germline <italic toggle="yes">CDKN2A</italic> mutations in these cases are rare (Bartsch et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0007" ref-type="bibr">2002</xref>).</p><p>Pancreatic cancer is one of the most aggressive tumors and its incidence and mortality are rapidly increasing. Only around 16% of patients have a resectable tumor at time of diagnosis. Around 94% of pancreatic cases develop in the exocrine tissue of the pancreas resulting in pancreatic ductal adenocarcinoma (PDAC). Other pancreatic cancer malignancies are rarer, such as (adeno)squamous carcinoma, colloid carcinoma, and neuroendocrine tumors (Klatte et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0071" ref-type="bibr">2022</xref>).</p><p>Pancreatic cancer is a multifactorial genetic disease. The general population has an average lifetime risk of pancreatic cancer of approximately 1.5%. Several high&#x02010;risk factors have been identified, such as smoking, daily alcohol consumption, and obesity (defined as BMI&#x02009;&#x02265;&#x02009;30); and patients related nonmodifiable parameters such as older age, male gender, African&#x02010;Americans ethnicity, non&#x02010;O blood group, diabetes, chronic pancreatitis, and genetic mutations (Abe et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0001" ref-type="bibr">2021</xref>).</p><p>When the lifetime risk of pancreatic cancer is higher than 5%, individuals are considered high&#x02010;risk individuals (HRI). Up to 10% of pancreatic cancers cases arise in HRI, which can be stratified as familial pancreatic cancer, namely patients with a strong family history, or as hereditary cancer syndrome, namely patients that are carriers of a germline mutation (Klatte et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0071" ref-type="bibr">2022</xref>). Pancreatic cancer is associated with both family and hereditary cancer syndromes (Abe et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0001" ref-type="bibr">2021</xref>).</p><p>Familial pancreatic cancer indicates a family clustering of pancreatic cancer with two or more first&#x02010;degree relatives with pancreatic cancer and without a known hereditary cancer syndrome. The risk to develop a pancreatic cancer increases with the number of affected family members: from a 4.6&#x02010;fold risk with one first&#x02010;degree relative to 32&#x02010;fold risk with three first&#x02010;degree relatives (Klatte et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0071" ref-type="bibr">2022</xref>). There are known germline pathogenic variants linked to hereditary pancreatic cancer, which is closely related to other hereditary tumor syndromes (Abe et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0001" ref-type="bibr">2021</xref>; Table&#x000a0;<xref rid="pcmr13210-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="pcmr13210-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Hereditary tumor syndromes associated with pancreatic tumor.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Cancer syndrome</th><th align="center" valign="bottom" rowspan="1" colspan="1">Relative risk for pancreatic cancer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Most frequent associated cancers</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description&#x02014;gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Role</th><th align="center" valign="bottom" rowspan="1" colspan="1">Specific function</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Familial Atypical Multiple Melanoma Mole (FAMMM) syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">13&#x02013;47.8</td><td align="center" valign="top" rowspan="1" colspan="1">Melanoma and non&#x02010;melanoma skin, oropharynx, respiratory</td><td align="center" valign="top" rowspan="1" colspan="1">CDKN2A (p<sup>16INK4a</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin&#x02010;dependent kinase inhibitor 2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cell cycle</td><td align="center" valign="top" rowspan="1" colspan="1">Deceleration of cell cycle by inhibition of CDK4 and phosphorylation of RB</td><td align="center" valign="top" rowspan="1" colspan="1">de Snoo et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0029" ref-type="bibr">2008</xref>); Helgadottir et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0055" ref-type="bibr">2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Familial Adenomatous Polyposis (FAP)</td><td align="center" valign="top" rowspan="1" colspan="1">4.5</td><td align="center" valign="top" rowspan="1" colspan="1">Gastrointestinal, brain, thyroid, hepatic</td><td align="center" valign="top" rowspan="1" colspan="1">APC</td><td align="center" valign="top" rowspan="1" colspan="1">Adenomatous Polyposis Coli</td><td align="center" valign="top" rowspan="1" colspan="1">Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibition of Wnt signaling pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Vasen et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0137" ref-type="bibr">2008</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ataxia&#x02010;telangiectasia (AT)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5</td><td align="center" valign="top" rowspan="1" colspan="1">Lymphoma, acute leukemia, breast</td><td align="center" valign="top" rowspan="1" colspan="1">ATM</td><td align="center" valign="top" rowspan="1" colspan="1">ataxia telangiectasia mutated</td><td align="center" valign="top" rowspan="1" colspan="1">DNA damage responses</td><td align="center" valign="top" rowspan="1" colspan="1">Regulation of double&#x02010;strand DNA break (DSB) signaling and stress responses</td><td align="center" valign="top" rowspan="1" colspan="1">Hsu et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0058" ref-type="bibr">2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hereditary Breast and Ovarian syndrome (HBOC)</td><td align="center" valign="top" rowspan="1" colspan="1">2.3&#x02013;10.0</td><td align="center" valign="top" rowspan="1" colspan="1">Breast, ovarian, prostate</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>BRCA1</p>
<p>BRCA2</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Breast Cancer susceptibility gene 1/2</td><td align="center" valign="top" rowspan="1" colspan="1">Genome stability</td><td align="center" valign="top" rowspan="1" colspan="1">Regulation of precise DNA repair by homologous recombination</td><td align="center" valign="top" rowspan="1" colspan="1">Nelson et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0098" ref-type="bibr">2013</xref>); van Asperen et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0133" ref-type="bibr">2005</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peutz&#x02010;Jeghers syndrome (PJS)</td><td align="center" valign="top" rowspan="1" colspan="1">132</td><td align="center" valign="top" rowspan="1" colspan="1">Colorectal, breast, small bowel, gastric</td><td align="center" valign="top" rowspan="1" colspan="1">STK11 (known also as LKB1)</td><td align="center" valign="top" rowspan="1" colspan="1">Serine/Threonine Kinase 11</td><td align="center" valign="top" rowspan="1" colspan="1">Cell polarity and energy metabolism</td><td align="center" valign="top" rowspan="1" colspan="1">STK11: Control of the activity of AMP&#x02010;activated protein kinase (AMPK) with the formation of heterotrimeric complex</td><td align="center" valign="top" rowspan="1" colspan="1">van Lier et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0135" ref-type="bibr">2010</xref>); Giardiello et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0046" ref-type="bibr">2000</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hereditary nonpolyposis colorectal cancer (Lynch syndrome)</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td><td align="center" valign="top" rowspan="1" colspan="1">Gastrointestinal, endometrial, urological</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>MLH1</p>
<p>MSH2</p>
<p>MSH6</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>MutL homolog 1</p>
<p>DNA mismatch repair protein Msh2/6</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">DNA mismatch repair</td><td align="center" valign="top" rowspan="1" colspan="1">Proteins responsible of DNA mismatch repair</td><td align="center" valign="top" rowspan="1" colspan="1">van Leerdam et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0134" ref-type="bibr">2019</xref>); Kastrinos et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0067" ref-type="bibr">2009</xref>); Watson et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0140" ref-type="bibr">2008</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Li&#x02010;Fraumeni syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td><td align="center" valign="top" rowspan="1" colspan="1">Breast, sarcoma, leukemia, adrenocortical, brain</td><td align="center" valign="top" rowspan="1" colspan="1">TP53 (p53)</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor protein P53</td><td align="center" valign="top" rowspan="1" colspan="1">Apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">Promotion of apoptosis after detection of DNA damage</td><td align="center" valign="top" rowspan="1" colspan="1">de Andrade et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0027" ref-type="bibr">2019</xref>); Ruijs et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0120" ref-type="bibr">2010</xref>)</td></tr></tbody></table><table-wrap-foot id="pcmr13210-ntgp-0003"><fn id="pcmr13210-note-0004"><p>
<italic toggle="yes">Note:</italic> Table was modified from Klatte et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0071" ref-type="bibr">2022</xref>).</p></fn></table-wrap-foot></table-wrap><p>In addition of the accurate described <italic toggle="yes">CDKN2A</italic> gene (Danishevich et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0024" ref-type="bibr">2023</xref>; Pauley et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0102" ref-type="bibr">2022</xref>), there are other genes found in literature that are associated with both melanoma and pancreatic cancers. Some genes responsible of tumor syndromes listed in Table&#x000a0;<xref rid="pcmr13210-tbl-0002" ref-type="table">2</xref> were also found mutated in melanoma patients. For example, a likely pathogenic mutation of the Peutz&#x02010;Jeghers syndrome gene, namely <italic toggle="yes">STK11</italic>, were found in primary melanoma (Rowan et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0119" ref-type="bibr">1999</xref>). STK11 can prevent melanoma cell invasion through the activation of the signal transducer and activator of STAT3/5 and FAK signaling pathways (Dzung et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0039" ref-type="bibr">2022</xref>; Azin and Demehri&#x000a0;<xref rid="pcmr13210-bib-0006" ref-type="bibr">2022</xref>). Malignant melanoma has been reported also in <italic toggle="yes">BRCA2</italic>&#x02010;mutated families (Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0063" ref-type="bibr">2019</xref>). Heterozygous and loss&#x02010;of&#x02010;function germline variants in <italic toggle="yes">ATM</italic> gene have been also associated with an increased lifetime risk of melanoma cancers (Borja et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0011" ref-type="bibr">2023</xref>).</p></sec><sec id="pcmr13210-sec-0003"><label>3</label><title>Somatic Alterations in Cutaneous Melanoma and Pancreatic cancer</title><p>Despite family and hereditary cases, the majority of melanoma and pancreatic cancer cases are attributable to randomly acquired genetic mutations, which can contribute to cancer development and metastasis progression. It is essential to identify the somatic driver mutations in tumors, because they play a critical role in early diagnosis, optimal management, precise prognostication and targeted therapy approaches.</p><p>In melanoma, several molecular factors, including non&#x02010;coding RNA and somatic mutations, have been associated with melanoma pathogenesis (Ribero et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0110" ref-type="bibr">2023</xref>; Durante et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0036" ref-type="bibr">2022</xref>, <xref rid="pcmr13210-bib-0037" ref-type="bibr">2021</xref>; Dika et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0032" ref-type="bibr">2020</xref>; Riefolo et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0115" ref-type="bibr">2019</xref>; Broseghini et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0013" ref-type="bibr">2021</xref>; Naddeo et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0097" ref-type="bibr">2024</xref>). Moreover, several genes have been found implicated in the activation of the MAPK pathway, affecting cell proliferation, differentiation and survival, and in PI3K/Akt pathway, affecting metabolism, proliferation, cell survival, growth and angiogenesis (Dika, Patrizi, et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0033" ref-type="bibr">2020</xref>). A genomic classification of melanoma is based on the presence or absence of somatic alterations of three genes. Specifically, melanomas can be classified into four genomic subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS (N&#x02010;, H&#x02010;, K&#x02010;), mutant NF1, and Triple&#x02010;wild type (Triple&#x02010;WT). The Triple&#x02010;WT group is enriched of KIT mutations, focal amplifications, and complex structural rearrangements. In addition, it lacks UV signature and manifests more copy number changes (Cancer Genome Atlas Network&#x000a0;<xref rid="pcmr13210-bib-0015" ref-type="bibr">2015</xref>). Other somatic mutations have been described in literature (Ravaioli et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0108" ref-type="bibr">2019</xref>; Lambertini, Mussi, and Dika&#x000a0;<xref rid="pcmr13210-bib-0076" ref-type="bibr">2021</xref>; Moscarella et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0094" ref-type="bibr">2019</xref>; Querzoli et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0107" ref-type="bibr">2023</xref>; Scarfi et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0124" ref-type="bibr">2020</xref>; Starace et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0128" ref-type="bibr">2018</xref>); Table&#x000a0;<xref rid="pcmr13210-tbl-0003" ref-type="table">3</xref> reports the most significant somatic driver mutations within the subtypes of primary melanoma, namely nonacral CM, which includes superficial spreading melanoma (SSM), nodular melanoma (NM), and lentigo maligna melanoma (LMM); desmoplastic melanoma, acral lentiginous melanoma (ALM), and mucosal melanoma.</p><table-wrap position="float" id="pcmr13210-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Most significant somatic driver mutations in cutaneous melanoma.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description&#x02014;gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pathway</th><th align="center" valign="bottom" rowspan="1" colspan="1">Protein type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Most frequent mutations&#x02010;alterations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Clinical phenotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">Prevalence of mutations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Consequences due to mutation</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">BRAF</td><td align="center" valign="top" rowspan="1" colspan="1">B&#x02010;Raf Proto&#x02010;Oncogene</td><td align="center" valign="top" rowspan="1" colspan="1">MAPK pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Serine/threonine protein kinase</td><td align="center" valign="top" rowspan="1" colspan="1">V600E, V600K, V600D, V600R; mutually exclusive of NRAS mutations</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma, younger patients, sites with intermittent sun exposure</td><td align="center" valign="top" rowspan="1" colspan="1">60% of melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Constitutive activation of MAPK signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Hawryluk and Tsao&#x000a0;(<xref rid="pcmr13210-bib-0053" ref-type="bibr">2014</xref>); Manzano et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0089" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NRAS</td><td align="center" valign="top" rowspan="1" colspan="1">Neuroblastoma RAS viral oncogene homolog</td><td align="center" valign="top" rowspan="1" colspan="1">MAPK pathway</td><td align="center" valign="top" rowspan="1" colspan="1">G&#x02010;regulatory protein</td><td align="center" valign="top" rowspan="1" colspan="1">Q61K, Q61R, Q61L; mutually exclusive of BRAF mutations</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma, non&#x02010;sun&#x02010;damaged skin regions, increased Breslow thickness, higher mitotic rates, lower incidence of ulceration</td><td align="center" valign="top" rowspan="1" colspan="1">15%&#x02013;30% of melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Constitutive activation of MAPK signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Cancer Genome Atlas Network&#x000a0;(<xref rid="pcmr13210-bib-0015" ref-type="bibr">2015</xref>); Hawryluk and Tsao&#x000a0;(<xref rid="pcmr13210-bib-0053" ref-type="bibr">2014</xref>); Manzano et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0089" ref-type="bibr">2016</xref>); Johnson and Puzanov&#x000a0;(<xref rid="pcmr13210-bib-0064" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NF1</td><td align="center" valign="top" rowspan="1" colspan="1">Neurofibromin 1</td><td align="center" valign="top" rowspan="1" colspan="1">MAPK pathway and PI3K pathways</td><td align="center" valign="top" rowspan="1" colspan="1">Negative regulator of RAS</td><td align="center" valign="top" rowspan="1" colspan="1">Loss&#x02010;of&#x02010;function mutation; coexisted with mutations of RASA1</td><td align="center" valign="top" rowspan="1" colspan="1">Desmoplastic melanomas, sun&#x02010;exposed melanomas and elderly patients</td><td align="center" valign="top" rowspan="1" colspan="1">14% of melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Constitutive activation of the MAPK and PI3K pathways</td><td align="center" valign="top" rowspan="1" colspan="1">Cancer Genome Atlas Network&#x000a0;(<xref rid="pcmr13210-bib-0015" ref-type="bibr">2015</xref>); Manzano et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0089" ref-type="bibr">2016</xref>); Kadokura et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0065" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KIT</td><td align="center" valign="top" rowspan="1" colspan="1">Proto&#x02010;oncogene receptor tyrosine kinase</td><td align="center" valign="top" rowspan="1" colspan="1">MAPK and PI3K/Akt pathways</td><td align="center" valign="top" rowspan="1" colspan="1">Transmembrane receptor tyrosine kinase</td><td align="center" valign="top" rowspan="1" colspan="1">Exon 11 (most often L576P), exon 13 (most often K642E); mutually exclusive of BRAF and NRAS mutations</td><td align="center" valign="top" rowspan="1" colspan="1">Acral lentigo melanoma, mucosal melanoma, chronically sun&#x02010;damaged surfaces</td><td align="center" valign="top" rowspan="1" colspan="1">3% of all melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Induction of both the MAPK and the PI3K pathways</td><td align="center" valign="top" rowspan="1" colspan="1">Carvajal et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0016" ref-type="bibr">2015</xref>); Curtin et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0022" ref-type="bibr">2006</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PTEN</td><td align="center" valign="top" rowspan="1" colspan="1">Phosphatase and Tensin homolog</td><td align="center" valign="top" rowspan="1" colspan="1">PI3K/Akt pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Phosphatidyl&#x02010;inositol&#x02010;3,4,5&#x02010;triphosphate 3&#x02010;phosphatase</td><td align="center" valign="top" rowspan="1" colspan="1">Frameshift mutation, chromosomal deletion; frequently coexist with BRAF mutations, but not with NRAS</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">14% of specimens in the TCGA melanoma cohort</td><td align="center" valign="top" rowspan="1" colspan="1">Activation of PI3K/Akt pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Cancer Genome Atlas Network&#x000a0;(<xref rid="pcmr13210-bib-0015" ref-type="bibr">2015</xref>); Shain et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0126" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MITF</td><td align="center" valign="top" rowspan="1" colspan="1">Microphthalmia&#x02010;associated transcription factor</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Melanogenesis,</p>
<p>MAPK pathway</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Basic helix&#x02013;loop&#x02013;helix/leucine zipper transcription factor</td><td align="center" valign="top" rowspan="1" colspan="1">M&#x02010;MITF isoform, MITF amplification</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">80% of melanomas 20% of metastatic melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Promotion tumorigenesis</td><td align="center" valign="top" rowspan="1" colspan="1">Garraway et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0044" ref-type="bibr">2005</xref>); Wellbrock and Arozarena&#x000a0;(<xref rid="pcmr13210-bib-0141" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PREX2</td><td align="center" valign="top" rowspan="1" colspan="1">Phosphatidylinositol&#x02010;3,4,5&#x02010;trisphosphate RAC exchanger 2</td><td align="center" valign="top" rowspan="1" colspan="1">PI3K/AKT pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Protein that activates the small GTPase Rac</td><td align="center" valign="top" rowspan="1" colspan="1">Truncated mutation</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">27% of the TCGA melanoma cohort</td><td align="center" valign="top" rowspan="1" colspan="1">Acceleration of tumor formation, activate RAC1 increased PI3K/AKT signaling, enhanced cell proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">Lissanu Deribe&#x000a0;(<xref rid="pcmr13210-bib-0084" ref-type="bibr">2016</xref>); Berger et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0008" ref-type="bibr">2012</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TERT</td><td align="center" valign="top" rowspan="1" colspan="1">Telomerase reverse transcriptase</td><td align="center" valign="top" rowspan="1" colspan="1">Telomere sustainment, chromosomal stability</td><td align="center" valign="top" rowspan="1" colspan="1">Catalytic subunit of the holoenzyme telomerase</td><td align="center" valign="top" rowspan="1" colspan="1">C228T, C250T (ultraviolet&#x02010;signature mutation) TERT promoter mutations are associated with BRAF and NRAS mutations</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">Sporadic primary melanomas (33%), metastatic melanomas (85%)</td><td align="center" valign="top" rowspan="1" colspan="1">Overcome replication&#x02010;induced senescence</td><td align="center" valign="top" rowspan="1" colspan="1">Huang et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0061" ref-type="bibr">2013</xref>); Horn et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0057" ref-type="bibr">2013</xref>); Griewank et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0049" ref-type="bibr">2014</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RAC1</td><td align="center" valign="top" rowspan="1" colspan="1">Rac Family Small GTPase 1</td><td align="center" valign="top" rowspan="1" colspan="1">Cellular cytoskeleton organization and motility</td><td align="center" valign="top" rowspan="1" colspan="1">RHO GTPase</td><td align="center" valign="top" rowspan="1" colspan="1">P29S (ultraviolet&#x02010;signature mutation)</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma, increased Breslow thickness, increased mitotic rate, ulceration, presence of lymph node metastases at the time of diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">5%&#x02013;9% of melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Cell proliferation, suppression of antitumor immune responses</td><td align="center" valign="top" rowspan="1" colspan="1">Vu et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0138" ref-type="bibr">2015</xref>); Mar et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0090" ref-type="bibr">2014</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RPS27</td><td align="center" valign="top" rowspan="1" colspan="1">Protein S27</td><td align="center" valign="top" rowspan="1" colspan="1">Translation regulation</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5&#x02032;&#x02010;UTR mutation</td><td align="center" valign="top" rowspan="1" colspan="1">Nonacral cutaneous melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">10% of melanomas</td><td align="center" valign="top" rowspan="1" colspan="1">Induction of the mTOR pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Dutton&#x02010;Regester et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0038" ref-type="bibr">2014</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCND1</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin D1</td><td align="center" valign="top" rowspan="1" colspan="1">Cell cycle</td><td align="center" valign="top" rowspan="1" colspan="1">Cell cycle control protein</td><td align="center" valign="top" rowspan="1" colspan="1">Amplification</td><td align="center" valign="top" rowspan="1" colspan="1">Acral lentigo melanoma, superficial spreading melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">44% of ALM and 6% of SSM</td><td align="center" valign="top" rowspan="1" colspan="1">Promotion of cell cycle entry</td><td align="center" valign="top" rowspan="1" colspan="1">Sauter et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0123" ref-type="bibr">2002</xref>)</td></tr></tbody></table></table-wrap><p>About 90% of PDCA occur in sporadic forms and clinical heterogeneity is a hallmark of this disease (Morani et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0093" ref-type="bibr">2020</xref>; Pompella et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0103" ref-type="bibr">2020</xref>). In addition, the genomic analysis has always been very difficult, since PDAC often contains only 5%&#x02013;20% of neoplastic cells and cancers with lower cellularity than 40% often have been excluded (Waddell et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0139" ref-type="bibr">2015</xref>). Nevertheless, genomic researches revealed four key driver genes that are characteristically found in most PDACs, namely <italic toggle="yes">KRAS</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">TP53</italic>, and <italic toggle="yes">SMAD4</italic> (Morani et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0093" ref-type="bibr">2020</xref>; Pompella et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0103" ref-type="bibr">2020</xref>). Specifically, PDACs present significantly recurrent mutations, namely gain&#x02010;of&#x02010;function mutation in <italic toggle="yes">KRAS</italic> oncogene; loss&#x02010;of&#x02010;function mutations in <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">TP53</italic> and <italic toggle="yes">SMAD4</italic> tumor suppressor genes (Pompella et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0103" ref-type="bibr">2020</xref>).</p><p>Also, other chromosomal alterations have been described, and specific genetic mutations are associated with characteristic subtypes of PDACs and their precursors (Table&#x000a0;<xref rid="pcmr13210-tbl-0004" ref-type="table">4</xref>). The precursor of the majority of PDACs is pancreatic intraepithelial neoplasia (PanIN), while only a minority arises from pancreatic cystic lesions, namely intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (Pompella et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0103" ref-type="bibr">2020</xref>). <italic toggle="yes">KRAS</italic> somatic mutations are frequently found also in low&#x02010;grade PanINs, while high&#x02010;grade PanINs display <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">TP53</italic> mutations, too. <italic toggle="yes">TP53</italic> and <italic toggle="yes">SMAD4</italic> inactivation seems to be the final events of the molecular cascade that lead to the transformation in PDAC. IPMNs are characterized especially by mutations in <italic toggle="yes">GNAS</italic> and <italic toggle="yes">KRAS</italic>. Similar to PanINs, <italic toggle="yes">TP53</italic> and <italic toggle="yes">SMAD4</italic> gene mutations could be seen as the latest molecular events to the PCDA transformation (Pompella et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0103" ref-type="bibr">2020</xref>).</p><table-wrap position="float" id="pcmr13210-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Most significant somatic driver mutations in pancreatic cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description&#x02014;gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pathway</th><th align="center" valign="bottom" rowspan="1" colspan="1">Protein type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Most frequent mutations&#x02010;alterations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Clinical phenotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">Prevalence of mutations in pancreatic adenocarcinoma</th><th align="center" valign="bottom" rowspan="1" colspan="1">Consequences due to mutation</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">KRAS</td><td align="center" valign="top" rowspan="1" colspan="1">Kirsten rat sarcoma viral oncogene homolog</td><td align="center" valign="top" rowspan="1" colspan="1">MAPK signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Small GTPase transductor protein</td><td align="center" valign="top" rowspan="1" colspan="1">Missense mutation, exons 2 and 3</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma; Intraductal papillary mucinous neoplasm; Pancreatic intraepithelial neoplasms</td><td align="center" valign="top" rowspan="1" colspan="1">70%&#x02013;95%</td><td align="center" valign="top" rowspan="1" colspan="1">Constitutively activation of KRAS and MAPK signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Cicenas et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>); Hayashi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0054" ref-type="bibr">2017</xref>); Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDKN2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin Dependent Kinase Inhibitor 2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cell cycle control</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin&#x02010;dependent kinase inhibitor</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivating mutation/LOH, homozygous deletion</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma; Intraductal papillary mucinous neoplasm; Pancreatic intraepithelial neoplasms</td><td align="center" valign="top" rowspan="1" colspan="1">49%&#x02013;98%</td><td align="center" valign="top" rowspan="1" colspan="1">Alteration of cell cycle</td><td align="center" valign="top" rowspan="1" colspan="1">Cicenas et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>); Hayashi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0054" ref-type="bibr">2017</xref>); Luo et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0086" ref-type="bibr">2013</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TP53</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor protein P53</td><td align="center" valign="top" rowspan="1" colspan="1">DNA damage response</td><td align="center" valign="top" rowspan="1" colspan="1">Regulatory protein</td><td align="center" valign="top" rowspan="1" colspan="1">Missense mutation/LOH</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma; Intraductal papillary mucinous neoplasm; Pancreatic intraepithelial neoplasms</td><td align="center" valign="top" rowspan="1" colspan="1">20%&#x02013;76%</td><td align="center" valign="top" rowspan="1" colspan="1">Loss of DNA binding ability and gene transcription activation, loss of apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">Cicenas et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>); Hayashi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0054" ref-type="bibr">2017</xref>); Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SMAD4</td><td align="center" valign="top" rowspan="1" colspan="1">SMAD family member 4</td><td align="center" valign="top" rowspan="1" colspan="1">TGF&#x003b2; signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Signal transduction proteins</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivating mutation/LOH, homozygous deletion</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">19%&#x02013;50%</td><td align="center" valign="top" rowspan="1" colspan="1">Alteration of TGF&#x003b2; pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Cicenas et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>); Hayashi et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0054" ref-type="bibr">2017</xref>); Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>); De Bosscher, Hill, and Nicolas&#x000a0;(<xref rid="pcmr13210-bib-0028" ref-type="bibr">2004</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GNAS</td><td align="center" valign="top" rowspan="1" colspan="1">Guanine Nucleotide binding protein Alpha Stimulating activity polypeptide</td><td align="center" valign="top" rowspan="1" colspan="1">G&#x02010;protein signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Component of G protein&#x02010;coupled receptor&#x02010;regulated adenylyl cyclase signal transduction pathways</td><td align="center" valign="top" rowspan="1" colspan="1">Missense mutation</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma; Intraductal papillary mucinous neoplasm</td><td align="center" valign="top" rowspan="1" colspan="1">2%&#x02013;11%</td><td align="center" valign="top" rowspan="1" colspan="1">Induction of PKA&#x02010;mediated SIK suppression and reprogramming lipid metabolism</td><td align="center" valign="top" rowspan="1" colspan="1">Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>); Patra et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0101" ref-type="bibr">2018</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BRCA1</td><td align="center" valign="top" rowspan="1" colspan="1">Breast cancer type 1 susceptibility protein</td><td align="center" valign="top" rowspan="1" colspan="1">DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">Nuclear phosphoprotein</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivating mutation/LOH</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">6.6%&#x02013;14%</td><td align="center" valign="top" rowspan="1" colspan="1">Alteration in DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">Cicenas et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>); Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>); Stadler et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0127" ref-type="bibr">2012</xref>); Knudsen et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0072" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BRCA2</td><td align="center" valign="top" rowspan="1" colspan="1">Breast cancer type 2 susceptibility protein</td><td align="center" valign="top" rowspan="1" colspan="1">DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">Nuclear phosphoprotein</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivating mutation/LOH</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">3.6%&#x02013;7.5%</td><td align="center" valign="top" rowspan="1" colspan="1">Alteration in DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">Cicenas et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>); Stadler et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0127" ref-type="bibr">2012</xref>); Friedenson&#x000a0;(<xref rid="pcmr13210-bib-0041" ref-type="bibr">2005</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RNF43</td><td align="center" valign="top" rowspan="1" colspan="1">Ring finger protein 43</td><td align="center" valign="top" rowspan="1" colspan="1">Ubiquitin signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Ubiquitin&#x02010;protein ligase</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivating mutation/LOH</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma; Intraductal papillary mucinous neoplasm</td><td align="center" valign="top" rowspan="1" colspan="1">10%&#x02013;15%</td><td align="center" valign="top" rowspan="1" colspan="1">Induction of constitutive activation of Wnt signaling</td><td align="center" valign="top" rowspan="1" colspan="1">Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ARID1A</td><td align="center" valign="top" rowspan="1" colspan="1">AT&#x02010;rich interaction domain 1A</td><td align="center" valign="top" rowspan="1" colspan="1">Chromatin remodeling</td><td align="center" valign="top" rowspan="1" colspan="1">Subunit of SWI/SNF protein complexes</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivating mutation/LOH</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">10%&#x02013;25%</td><td align="center" valign="top" rowspan="1" colspan="1">Disruption of the f SWI/SNF chromatin remodeling complex</td><td align="center" valign="top" rowspan="1" colspan="1">Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>); Witkiewicz et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0144" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SLIT2</td><td align="center" valign="top" rowspan="1" colspan="1">Slit Guidance Ligand 2</td><td align="center" valign="top" rowspan="1" colspan="1">Axon guidance</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Mutation/LOH</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">5%&#x02013;15% o</td><td align="center" valign="top" rowspan="1" colspan="1">Regulation of tumor angiogenesis, cell invasion, metastasis, and nerve infiltration</td><td align="center" valign="top" rowspan="1" colspan="1">Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>); Ding et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0034" ref-type="bibr">2020</xref>); Secq et&#x000a0;al.&#x000a0;(<xref rid="pcmr13210-bib-0125" ref-type="bibr">2015</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MYC</td><td align="center" valign="top" rowspan="1" colspan="1">Myelocytomatosis oncogene</td><td align="center" valign="top" rowspan="1" colspan="1">Transcriptional regulation</td><td align="center" valign="top" rowspan="1" colspan="1">Nuclear phosphoprotein</td><td align="center" valign="top" rowspan="1" colspan="1">Amplification</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreatic Ductal Adeno Carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">10%&#x02013;15%</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor promotion</td><td align="center" valign="top" rowspan="1" colspan="1">Wood, Yurgelun, and Goggins&#x000a0;(<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>)</td></tr></tbody></table></table-wrap><p>As reported, sporadic CM and sporadic pancreatic cancer seem to be characterized by different key&#x02010;driven genes. Interestingly, genetic alterations in <italic toggle="yes">CDKN2A</italic> gene are frequently found in both familial and sporadic pancreatic cancer (Tables&#x000a0;<xref rid="pcmr13210-tbl-0002" ref-type="table">2</xref> and <xref rid="pcmr13210-tbl-0004" ref-type="table">4</xref>) while in melanoma, this gene is mostly associated with the familial form (Table&#x000a0;<xref rid="pcmr13210-tbl-0001" ref-type="table">1</xref>). These data suggested that the link between these two tumors is mostly at germline mutation levels.</p></sec><sec id="pcmr13210-sec-0004"><label>4</label><title>Open&#x02010;Access Cancer Genomics Analysis in Melanoma and Pancreatic Cancer</title><p>To deepen and investigate the genetic landscape of these two cancers, an open&#x02010;access and open&#x02010;source resource, namely cBioPortal for Cancer Genomics (<ext-link xlink:href="https://genie.cbioportal.org" ext-link-type="uri">https://genie.cbioportal.org</ext-link>), has been used to explore multidimensional cancer genomics datasets. Specifically, the last AACR Project GENIE registry (GENIE 15.0&#x02010;public, which was released in January 2024) has been used and investigated. This registry is one of the largest fully public cancer genomic datasets released to date, which includes approximately 198,000 sequenced samples from more than 172,000 patients (<ext-link xlink:href="https://www.aacr.org/professionals/research/aacr-project-genie/aacr-project-genie-data/" ext-link-type="uri">https://www.aacr.org/professionals/research/aacr&#x02010;project&#x02010;genie/aacr&#x02010;project&#x02010;genie&#x02010;data/</ext-link>).</p><p>Among the 198,041 samples, we selected and analyzed (March 1, 2024) melanoma samples (melanoma <italic toggle="yes">n</italic>&#x02009;=&#x02009;4218, CM <italic toggle="yes">n</italic>&#x02009;=&#x02009;2193) and pancreatic cancer samples (pancreatic adenocarcinoma <italic toggle="yes">n</italic>&#x02009;=&#x02009;7261, pancreatic neuroendocrine tumor <italic toggle="yes">n</italic>&#x02009;=&#x02009;689, adenosquamous carcinoma of the pancreas <italic toggle="yes">n</italic>&#x02009;=&#x02009;123). For both tumor types, we collected mutated genes with a frequency&#x02009;&#x02265;&#x02009;5% and copy number alterations (CNA) with a frequency&#x02009;&#x02265;&#x02009;3%.</p><p>For melanoma, 253 mutated genes with a frequency&#x02009;&#x02265;&#x02009;5% were found and 169 of them were found in more than 1000 samples (Table&#x000a0;<xref rid="pcmr13210-supitem-0001" ref-type="supplementary-material">S1</xref>). Fifteen mutated genes are highly frequent (frequency&#x02009;&#x0003e;&#x02009;20%) in melanomas and include the three genes used for genetic classification of melanoma, namely <italic toggle="yes">BRAF</italic> (frequency&#x02009;=&#x02009;38.4%), <italic toggle="yes">NRAS</italic> (frequency&#x02009;=&#x02009;24.8%), and <italic toggle="yes">NF1</italic> (frequency&#x02009;=&#x02009;21.8%). The other genes are <italic toggle="yes">TERT</italic> (frequency&#x02009;=&#x02009;50.3%), <italic toggle="yes">LRP1B</italic> (frequency&#x02009;=&#x02009;34.7%), <italic toggle="yes">PTPRT</italic> (frequency&#x02009;=&#x02009;29.4%), <italic toggle="yes">SPTA1</italic> (frequency&#x02009;=&#x02009;25.0%), <italic toggle="yes">MECOM</italic> (frequency&#x02009;=&#x02009;24.6%), <italic toggle="yes">GRIN2A</italic> (frequency&#x02009;=&#x02009;24.0%), <italic toggle="yes">PREX2</italic> (frequency&#x02009;=&#x02009;24.0%), <italic toggle="yes">KMT2D</italic> (frequency&#x02009;=&#x02009;22.7%), <italic toggle="yes">PTPRD</italic> (frequency&#x02009;=&#x02009;21.8%), <italic toggle="yes">GLI2</italic> (frequency&#x02009;=&#x02009;20.3%), <italic toggle="yes">ROS1</italic> (frequency&#x02009;=&#x02009;20.1%), and <italic toggle="yes">PAK5</italic> (frequency&#x02009;=&#x02009;20.0%).</p><p>For pancreatic cancer, we found 27 mutated genes with a frequency&#x02009;&#x02265;&#x02009;5% (Table&#x000a0;<xref rid="pcmr13210-supitem-0002" ref-type="supplementary-material">S2</xref>). Among them, 12 have been profiled in more than 1000 samples. The four most frequent mutations are those confirmed in sporadic pancreatic cancer by literature, namely <italic toggle="yes">KRAS</italic> (frequency&#x02009;=&#x02009;78.9%), <italic toggle="yes">TP53</italic> (frequency&#x02009;=&#x02009;64.0%), <italic toggle="yes">SMAD4</italic> (frequency&#x02009;=&#x02009;18.2%) and <italic toggle="yes">CDKN2A</italic> (frequency&#x02009;=&#x02009;9.4%). Other frequent mutations occur in already described <italic toggle="yes">ARID1A</italic> gene (frequency&#x02009;=&#x02009;8.3%) and <italic toggle="yes">RNF43</italic> (frequency&#x02009;=&#x02009;5.9%). Interestingly, <italic toggle="yes">LRP1B</italic> (low&#x02010;density lipoprotein receptor&#x02010;related protein 1B) gene has a frequency of 9.0%.</p><p>We compared the mutated genes in melanoma and pancreatic cancer, and we reported the 18 common mutated genes in Table&#x000a0;<xref rid="pcmr13210-tbl-0005" ref-type="table">5</xref>, where number of profiled samples and frequency of the mutated gene are indicated in both tumors.</p><table-wrap position="float" id="pcmr13210-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Common mutated genes in melanoma and pancreatic cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Gene</th><th align="center" rowspan="2" valign="bottom" colspan="1">Description&#x02014;gene name</th><th align="center" rowspan="2" valign="bottom" colspan="1">Pathway</th><th align="center" colspan="2" valign="bottom" rowspan="1">Melanoma</th><th align="center" colspan="2" valign="bottom" rowspan="1">Pancreatic cancer</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Frequency</th><th align="center" valign="bottom" rowspan="1" colspan="1">Profiled samples (<italic toggle="yes">n</italic>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Frequency</th><th align="center" valign="bottom" rowspan="1" colspan="1">Profiled samples (<italic toggle="yes">n</italic>)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">ADGRL3</td><td align="center" valign="top" rowspan="1" colspan="1">Adhesion G Protein&#x02010;coupled receptor L3</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of synaptic function</td><td align="center" valign="top" rowspan="1" colspan="1">5.3%</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">5.5%</td><td align="center" valign="top" rowspan="1" colspan="1">55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ANKRD24</td><td align="center" valign="top" rowspan="1" colspan="1">Ankyrin repeat domain 24</td><td align="center" valign="top" rowspan="1" colspan="1">Unknown molecular role</td><td align="center" valign="top" rowspan="1" colspan="1">5.4%</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">13.0%</td><td align="center" valign="top" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ARID1A</td><td align="center" valign="top" rowspan="1" colspan="1">Chromatin remodeling gene AT&#x02010;rich interactive domain 1A</td><td align="center" valign="top" rowspan="1" colspan="1">SWI/SNF complex, chromatin regulator</td><td align="center" valign="top" rowspan="1" colspan="1">10.7%</td><td align="center" valign="top" rowspan="1" colspan="1">4269</td><td align="center" valign="top" rowspan="1" colspan="1">8.3%</td><td align="center" valign="top" rowspan="1" colspan="1">7303</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BOD1L1</td><td align="center" valign="top" rowspan="1" colspan="1">Biorientation of chromosomes in cell division 1 like 1</td><td align="center" valign="top" rowspan="1" colspan="1">Replication fork protection factor</td><td align="center" valign="top" rowspan="1" colspan="1">7.1%</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">11.1%</td><td align="center" valign="top" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDH23</td><td align="center" valign="top" rowspan="1" colspan="1">Cadherin&#x02010;23</td><td align="center" valign="top" rowspan="1" colspan="1">Mediator of homotypic and heterotypic cell&#x02013;cell adhesions</td><td align="center" valign="top" rowspan="1" colspan="1">12.7%</td><td align="center" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">15.6%</td><td align="center" valign="top" rowspan="1" colspan="1">77</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDKN2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin&#x02010;dependent kinase inhibitor 2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cell cycle</td><td align="center" valign="top" rowspan="1" colspan="1">9.4%</td><td align="center" valign="top" rowspan="1" colspan="1">6222</td><td align="center" valign="top" rowspan="1" colspan="1">9.4%</td><td align="center" valign="top" rowspan="1" colspan="1">8041</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DNAH9</td><td align="center" valign="top" rowspan="1" colspan="1">Dynein axonemal heavy chain 9</td><td align="center" valign="top" rowspan="1" colspan="1">Cell&#x02013;cell adhesion</td><td align="center" valign="top" rowspan="1" colspan="1">16.7%</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">17.9%</td><td align="center" valign="top" rowspan="1" colspan="1">84</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KDM6B</td><td align="center" valign="top" rowspan="1" colspan="1">Lysine demethylase 6B</td><td align="center" valign="top" rowspan="1" colspan="1">Epigenetic modifier</td><td align="center" valign="top" rowspan="1" colspan="1">8.5%</td><td align="center" valign="top" rowspan="1" colspan="1">246</td><td align="center" valign="top" rowspan="1" colspan="1">5.4%</td><td align="center" valign="top" rowspan="1" colspan="1">410</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KMT2D</td><td align="center" valign="top" rowspan="1" colspan="1">Lysine methyltransferase 2D</td><td align="center" valign="top" rowspan="1" colspan="1">H3K4 methylation</td><td align="center" valign="top" rowspan="1" colspan="1">22.7%</td><td align="center" valign="top" rowspan="1" colspan="1">4110</td><td align="center" valign="top" rowspan="1" colspan="1">7.0%</td><td align="center" valign="top" rowspan="1" colspan="1">7127</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LAMB4</td><td align="center" valign="top" rowspan="1" colspan="1">Laminin subunit beta 4</td><td align="center" valign="top" rowspan="1" colspan="1">Constituent of the extracellular matrix</td><td align="center" valign="top" rowspan="1" colspan="1">5.6%</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">5.4%</td><td align="center" valign="top" rowspan="1" colspan="1">147</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LRP1B</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#x02010;density lipoprotein receptor&#x02010;related protein 1B</td><td align="center" valign="top" rowspan="1" colspan="1">LDL receptor family signaling</td><td align="center" valign="top" rowspan="1" colspan="1">34.7%</td><td align="center" valign="top" rowspan="1" colspan="1">1470</td><td align="center" valign="top" rowspan="1" colspan="1">9.0%</td><td align="center" valign="top" rowspan="1" colspan="1">1267</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PDE4DIP</td><td align="center" valign="top" rowspan="1" colspan="1">Phosphodiesterase 4D interacting protein</td><td align="center" valign="top" rowspan="1" colspan="1">Endoplasmic reticulum&#x02010;to&#x02010;Golgi traffic</td><td align="center" valign="top" rowspan="1" colspan="1">6.2%</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">5.7%</td><td align="center" valign="top" rowspan="1" colspan="1">209</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PKD1L2</td><td align="center" valign="top" rowspan="1" colspan="1">Polycystin 1 Like 2 (gene/pseudogene)</td><td align="center" valign="top" rowspan="1" colspan="1">Probably function as a G&#x02010;protein&#x02010;coupled component or regulator of cation channel pores</td><td align="center" valign="top" rowspan="1" colspan="1">10.7%</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">14.8%</td><td align="center" valign="top" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRKDC</td><td align="center" valign="top" rowspan="1" colspan="1">Protein kinase, DNA&#x02010;activated, catalytic subunit</td><td align="center" valign="top" rowspan="1" colspan="1">DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">14.5%</td><td align="center" valign="top" rowspan="1" colspan="1">2526</td><td align="center" valign="top" rowspan="1" colspan="1">5.5%</td><td align="center" valign="top" rowspan="1" colspan="1">2934</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RANBP2</td><td align="center" valign="top" rowspan="1" colspan="1">Ran&#x02010;binding protein 2</td><td align="center" valign="top" rowspan="1" colspan="1">Nuclear pore complex</td><td align="center" valign="top" rowspan="1" colspan="1">10.2%</td><td align="center" valign="top" rowspan="1" colspan="1">1015</td><td align="center" valign="top" rowspan="1" colspan="1">5.4%</td><td align="center" valign="top" rowspan="1" colspan="1">958</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SPTA1</td><td align="center" valign="top" rowspan="1" colspan="1">Spectrin alpha, erythrocytic 1</td><td align="center" valign="top" rowspan="1" colspan="1">cytoskeletal protein</td><td align="center" valign="top" rowspan="1" colspan="1">25.0%</td><td align="center" valign="top" rowspan="1" colspan="1">1407</td><td align="center" valign="top" rowspan="1" colspan="1">5.8%</td><td align="center" valign="top" rowspan="1" colspan="1">1191</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TGF&#x02010;&#x003b2;1</td><td align="center" valign="top" rowspan="1" colspan="1">Transforming growth factor beta 1</td><td align="center" valign="top" rowspan="1" colspan="1">Activation of SMAD family transcription factors</td><td align="center" valign="top" rowspan="1" colspan="1">7.1%</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">5.6%</td><td align="center" valign="top" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TP53</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor protein P53</td><td align="center" valign="top" rowspan="1" colspan="1">DNA damage response</td><td align="center" valign="top" rowspan="1" colspan="1">18.8%</td><td align="center" valign="top" rowspan="1" colspan="1">6356</td><td align="center" valign="top" rowspan="1" colspan="1">64.0%</td><td align="center" valign="top" rowspan="1" colspan="1">8046</td></tr></tbody></table></table-wrap><p>In addition to the thoroughly described <italic toggle="yes">CDKN2A</italic>, which has been found in melanoma and pancreatic cancer with the same frequency (9.4%) in AACR Project GENIE registry, data showed other interestingly and relevant genes, since they were profiled in many samples (more than 900 samples for both groups) and found highly mutated.</p><p>First, there is <italic toggle="yes">TP53</italic> that is one of the most frequently mutated gene in cancer. The inactivation of the gene leads to the loss of the tumor suppressor action of the protein and can show additional oncogenic functions that give growth and survival advantages. More than 60% of pancreatic cancer cases present at least one mutation in these gene. These data are in agreement with the literature, where <italic toggle="yes">TP53</italic> is described as one of the four most mutated genes in sporadic pancreatic cancer (Cicenas et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0019" ref-type="bibr">2017</xref>; Wood, Yurgelun, and Goggins&#x000a0;<xref rid="pcmr13210-bib-0146" ref-type="bibr">2019</xref>). In AACR Project GENIE registry, 18.8% of melanomas showed at least a mutation in <italic toggle="yes">TP53</italic>. In literature, it was observed that there is a higher prevalence of mutant p53 in metastatic melanoma compared to primary tumors (Khan et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0070" ref-type="bibr">2023</xref>; Ricci et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0112" ref-type="bibr">2020</xref>). Mutated <italic toggle="yes">TP53</italic> is also responsible for a mixed cancer syndrome, namely Li&#x02010;Fraumeni syndrome, which leads to develop several different types of cancers, including melanoma (Toussi et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0132" ref-type="bibr">2020</xref>).</p><p>Another gene that is often mutated in several cancers is <italic toggle="yes">LRP1B</italic>, specifically, this gene is frequently inactivated at both genetic and epigenetic levels. <italic toggle="yes">LRP1B</italic> encodes for a cell surface receptor and is broadly expressed in multiple normal tissues. <italic toggle="yes">LRP1B</italic> is a member of LDLR protein family with a wide range of biological functions from cargo transport to cell signaling (Principe et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0105" ref-type="bibr">2021</xref>). Data from Genie registry showed that <italic toggle="yes">LRP1B</italic> is frequently mutated in both melanoma samples (34.7%) and pancreatic cancer cases (9%). Inactivation of this gene was also reported in melanoma (Nikolaev et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0099" ref-type="bibr">2011</xref>) and some single nucleotide polymorphism have been significantly associated with pancreas cancer risk in literature (Cotterchio et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0021" ref-type="bibr">2015</xref>).</p><p>27% of melanomas and 7% of pancreatic cancers in GENIE cohort showed mutation in <italic toggle="yes">KMT2D</italic> gene, also known as mixed&#x02010;lineage leukemia protein 4 (<italic toggle="yes">MLL4</italic>), which is one of the most frequently mutated genes in human cancer. KMT2D is a highly conserved catalytic component of the mammalian complex of protein associated with Set1 (COMPASS) complex, and is responsible for catalyzing H3K4me1 at transcription enhancers throughout the human genome (Lin&#x02010;Shiao et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0083" ref-type="bibr">2018</xref>). <italic toggle="yes">KMT2D</italic> mutant melanomas have been described in literature, where it was found that <italic toggle="yes">KMT2D</italic> loss promotes tumorigenesis by facilitating an increased use of the glycolysis pathway (Murugesan and Maitituoheti&#x000a0;<xref rid="pcmr13210-bib-0096" ref-type="bibr">2021</xref>). High mutation rates of KMT2D have been reported also in pancreatic cancer (Froimchuk, Jang, and Ge&#x000a0;<xref rid="pcmr13210-bib-0042" ref-type="bibr">2017</xref>). However, the prognostic role of <italic toggle="yes">KMT2D</italic> in pancreatic cancers is ambiguous, with contrasting reported in different studies (Sausen et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0122" ref-type="bibr">2015</xref>; Dawkins et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0026" ref-type="bibr">2016</xref>; Koutsioumpa et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0074" ref-type="bibr">2019</xref>).</p><p>
<italic toggle="yes">SPTA1</italic> gene encodes a cytoskeletal protein that affects cell and tissue growth and development by regulating YAP, an effector on the Hippo signaling pathway. This gene is mostly known as associated with Hereditary spherocytosis. Mutations on this gene were found in both pancreatic cancer, where it served as independent prognostic factor (Kou et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0073" ref-type="bibr">2023</xref>) and melanoma (Zhou et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0154" ref-type="bibr">2021</xref>). However, data about role of this gene in cancer are still poor, although they are frequently mutations in this gene in GENIE cohort of melanoma (25%) and pancreatic cancer (5.8%) samples.</p><p>Other four genes showed a frequency between 5% and 15% in a large number of tested melanoma and pancreatic cancer samples, namely <italic toggle="yes">ARID1A</italic>, <italic toggle="yes">PDE4DIP</italic>, <italic toggle="yes">PRKDC</italic>, and <italic toggle="yes">RANBP2</italic>.</p><p>ARID1A belongs to a class of chromatin regulatory proteins and was found mutated in both melanoma cases (10.7%) and pancreatic cancer samples (8.3%) in AACR Project GENIE registry. <italic toggle="yes">ARID1A</italic> role in cancer is highly variable since its alterations can have a tumor suppressive or oncogenic role, depending on the tumor type and context. ARID1A loss is generally associated with disease progression more often than onset (Fontana et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0040" ref-type="bibr">2023</xref>). In melanoma, <italic toggle="yes">ARID1A</italic> mutations are distributed across the gene without clustering or hotspots, and <italic toggle="yes">ARID1A&#x02010;</italic>mutated melanomas exhibit higher tumor mutational burden (TMB) compared to <italic toggle="yes">ARID1A</italic> wild&#x02010;type melanomas (Thielmann et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0131" ref-type="bibr">2022</xref>). In pancreatic ductal adenocarcinoma, <italic toggle="yes">ARID1A</italic> and <italic toggle="yes">KRAS</italic> have been found as co&#x02010;mutated, suggesting that the inactivation of ARID1A may cooperate with KRAS in the early stages of pancreatic cancer formation (Birnbaum et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0010" ref-type="bibr">2011</xref>).</p><p>
<italic toggle="yes">PDE4DIP</italic> also known as myomegalin (<italic toggle="yes">MMGL</italic>) is a component of AKAP&#x02010;PKA&#x02010;PDE4D signaling complex, which anchors the sequestering components of the cAMP&#x02010;dependent pathway to Golgi and/or centrosomes. Somatic mutations in <italic toggle="yes">PDE4DIP</italic> gene have been found in some cancers, including melanoma and pancreatic cancer; however, <italic toggle="yes">PDE4DIP</italic> literature is still poor (Li et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0080" ref-type="bibr">2023</xref>). In AACR Project GENIE registry, the frequency is between 5% and 6% for both melanoma and pancreatic cancer.</p><p>
<italic toggle="yes">PRKDC</italic> mutations have been detected in a high portion of melanoma samples (14.5%) and in 5.5% of tested pancreatic cancers. This gene encodes a protein that plays an important role in nonhomologous end joining (NHEJ) of DNA double&#x02010;strand breaks (DSBs) and is also closely related to the establishment of central immune tolerance and the maintenance of chromosome stability. There are emerging functions of this gene in the initiation and progression of cancer. Interestingly, the silencing of the <italic toggle="yes">PRKDC</italic> product by microRNAs sensitizes tumor cells to gemcitabine in pancreatic cancer cells (Hu et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0059" ref-type="bibr">2017</xref>) and cisplatin in melanoma cells (Li et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0079" ref-type="bibr">2017</xref>), respectively.</p><p>The nucleoporin <italic toggle="yes">RANBP2</italic> is a key component of the nuclear pore complex that regulates the nucleocytoplasmic transport. In GENIE cohort, this gene has been found mutated in 10.2% of melanoma samples and in 5.4% pancreatic cancer samples. Both tumor suppressor and oncogenic role have been described for <italic toggle="yes">RANBP2</italic> in cancer. A rare form of melanoma is the primary malignant melanoma of the esophagus (PMME). In this tumor, <italic toggle="yes">RANBP2</italic> gene has been found recurrently mutated and is considered one of the driver mutated genes. Moreover, all <italic toggle="yes">RANBP2</italic> mutations were putatively deleterious (Li et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0078" ref-type="bibr">2022</xref>).</p><p>Finally, other mutations have been found localized in several genes in a smaller number of tested melanoma and pancreatic cancer samples (<italic toggle="yes">n</italic>&#x02009;&#x0003c;&#x02009;200), including ADGRL3, ANKRD24, BOD1L1, CDH23, DNAH9, KDM6B, LAMB4, PKD1L2, and TGF&#x02010;&#x003b2;1. Literature about ADGRL3, ANKRD24, BOD1L1, LAMB4, and PKD1L2 in melanoma and in pancreatic cancer is still missing, while the other genes of this list have been already studied in these two tumors.</p><p>Through high&#x02010;throughput sequencing, <italic toggle="yes">CDH23</italic> has been identified as a promising susceptibility gene in hereditary melanoma. Evaluating its expression in sporadic melanoma by using the TCGA dataset, <italic toggle="yes">CDH23</italic> was found downregulated and its loss was associated with worse survival (Campos et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0014" ref-type="bibr">2020</xref>). In pancreatic cancer, findings suggest that overexpression of <italic toggle="yes">CDH23</italic> is likely to be related to the PDCA biological aggressiveness (Taniuchi et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0130" ref-type="bibr">2005</xref>). <italic toggle="yes">DNAH9</italic> product is involved in cell&#x02010;to&#x02010;cell adhesion and markedly affects cancer cell invasion and migration. <italic toggle="yes">DNAH9</italic> gene has been used in a support vector machine signature, which can predict relapse and survival in patients with early&#x02010;stage pancreatic ductal adenocarcinoma (Huang et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0062" ref-type="bibr">2023</xref>). <italic toggle="yes">KDM6B</italic> belongs to lysine demethylases (KDMs) family that removes methyl groups on lysine (K) amino acids of histones. The aberrant KDMs&#x02019; activity affects epigenetic modifications and is found in a variety of cancers, including pancreatic cancer and melanoma. In pancreatic cancer, loss of <italic toggle="yes">KDM6B</italic> enhances aggressiveness of pancreatic cancer (Yamamoto et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0148" ref-type="bibr">2014</xref>). In melanoma, <italic toggle="yes">KDM6B</italic> activity leads to upregulation of various targets of both NF&#x02010;&#x003ba;B and BMP that results in promotion of cell migration and metastasis development (Karami Fath et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0066" ref-type="bibr">2022</xref>). In addition, <italic toggle="yes">KDM6B</italic> expression has been found as positive associated with immune infiltration level of Treg in both pancreatic cancer and melanoma (Ding et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0035" ref-type="bibr">2022</xref>). <italic toggle="yes">TGF&#x02010;&#x003b2;1</italic> plays a complex role in carcinogenesis, including in melanoma. In fact, increased circulating TGF&#x02010;&#x003b2;1 is associated with impairment in NK cell effector functions in metastatic melanoma patients (Mirjacic Martinovic et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0092" ref-type="bibr">2022</xref>). In pancreatic cancer, <italic toggle="yes">TGF&#x02010;&#x003b2;1</italic> promotes autophagy that promoted proliferation and inhibited migration in SMAD4&#x02010;positive PDAC cells by decreasing the nuclear translocation of SMAD4, while it inhibited proliferation and promoted migration in SMAD4&#x02010;negative cells through the regulation of MAPK/ERK activation (Liang et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0081" ref-type="bibr">2020</xref>).</p><p>To further investigate genes involved in the pathogenesis of melanoma and pancreatic cancer, we searched for patients who had both cancers in AACR Project GENIE registry. We found two patients: the first patient with the ID code GENIE&#x02010;DFCI&#x02010;202272 (<ext-link xlink:href="https://genie.cbioportal.org/patient/summary?studyId=genie_public&#x00026;caseId=GENIE-DFCI-202272" ext-link-type="uri">https://genie.cbioportal.org/patient/summary?studyId=genie_public&#x00026;caseId=GENIE&#x02010;DFCI&#x02010;202272</ext-link>) develops a primary pancreatic adenocarcinoma (GENIE&#x02010;DFCI&#x02010;202272&#x02010;2710284) and melanoma metastasis (GENIE&#x02010;DFCI&#x02010;202272&#x02010;4192215), while the second patient with ID code GENIE&#x02010;DFCI&#x02010;089908 (<ext-link xlink:href="https://genie.cbioportal.org/patient/summary?studyId=genie_public&#x00026;caseId=GENIE-DFCI-089908" ext-link-type="uri">https://genie.cbioportal.org/patient/summary?studyId=genie_public&#x00026;caseId=GENIE&#x02010;DFCI&#x02010;089908</ext-link>) develops a primary melanoma (GENIE&#x02010;DFCI&#x02010;089908&#x02010;282415) and presents a metastasis form pancreatic adenocarcinoma (GENIE&#x02010;DFCI&#x02010;089908&#x02010;2970125). In both patients, we focused and reported mutated genes present in both tumors (Table&#x000a0;<xref rid="pcmr13210-tbl-0006" ref-type="table">6</xref>), because there might be some germline mutations that could predispose to melanoma and pancreatic cancer development.</p><table-wrap position="float" id="pcmr13210-tbl-0006" content-type="TABLE"><label>TABLE 6</label><caption><p>Common mutated genes in pancreatic cancer and melanoma from the same patient.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Patient</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">Name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pathway/role</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mutation type</th><th align="center" valign="bottom" rowspan="1" colspan="1">HGVSg<xref rid="pcmr13210-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Protein change</th><th align="center" valign="bottom" rowspan="1" colspan="1">ClinVar (ClinVar ID)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="5" valign="top" colspan="1">GENIE&#x02010;DFCI&#x02010;202272 (primary pancreatic adenocarcinoma and melanoma metastasis)</td><td align="center" valign="top" rowspan="1" colspan="1">BRCA2</td><td align="center" valign="top" rowspan="1" colspan="1">Breast cancer gene 2</td><td align="center" valign="top" rowspan="1" colspan="1">DNA damage response</td><td align="center" valign="top" rowspan="1" colspan="1">Frameshift deletion</td><td align="center" valign="top" rowspan="1" colspan="1">13:g.32911659_32911663del</td><td align="center" valign="top" rowspan="1" colspan="1">K1057Tfs*8</td><td align="center" valign="top" rowspan="1" colspan="1">Pathogenic (ClinVar ID: 37826)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">NOTCH1</td><td align="center" valign="top" rowspan="1" colspan="1">Neurogenic locus notch homolog protein 1</td><td align="center" valign="top" rowspan="1" colspan="1">Notch signaling, promotion of differentiation of progenitor cells into astroglia</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">9:g.139390828T&#x0003e;C</td><td align="center" valign="top" rowspan="1" colspan="1">T2455A</td><td align="center" valign="top" rowspan="1" colspan="1">Conflicting interpretations of pathogenicity: Uncertain significance (5) vs. Benign (1) (ClinVar ID: 264349)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">PDGFRA</td><td align="center" valign="top" rowspan="1" colspan="1">Platelet&#x02010;derived growth factor receptor alpha</td><td align="center" valign="top" rowspan="1" colspan="1">Tyrosine kinase receptor for members of the platelet&#x02010;derived growth factor family</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">4:g.55124981A&#x0003e;T</td><td align="center" valign="top" rowspan="1" colspan="1">T16S</td><td align="center" valign="top" rowspan="1" colspan="1">Conflicting interpretations of pathogenicity: Uncertain significance (3) vs. Likely benign (1) (ClinVar ID: 135017)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">ASXL1</td><td align="center" valign="top" rowspan="1" colspan="1">ASXL transcriptional regulator 1</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of chromatin remodeling</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">20:g.31023065A&#x0003e;T</td><td align="center" valign="top" rowspan="1" colspan="1">E850D</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">RIF1</td><td align="center" valign="top" rowspan="1" colspan="1">Replication timing regulatory factor 1</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of telomere length, DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">2:g.152320874A&#x0003e;C</td><td align="center" valign="top" rowspan="1" colspan="1">I1614L</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="5" valign="top" colspan="1">GENIE&#x02010;DFCI&#x02010;089908 (primary melanoma and pancreatic adenocarcinoma metastasis)</td><td align="center" valign="top" rowspan="1" colspan="1">FANCA</td><td align="center" valign="top" rowspan="1" colspan="1">FA Complementation Group A</td><td align="center" valign="top" rowspan="1" colspan="1">DNA repair</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">16:g.89811368C&#x0003e;T</td><td align="center" valign="top" rowspan="1" colspan="1">D1209N</td><td align="center" valign="top" rowspan="1" colspan="1">Uncertain significance (ClinVar ID: 2180921)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SBDS</td><td align="center" valign="top" rowspan="1" colspan="1">SBDS ribosome maturation Factor, also known as Shwachman&#x02013;Bodian&#x02013;Diamond Syndrome Protein</td><td align="center" valign="top" rowspan="1" colspan="1">Ribosome biogenesis</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">7:g.66453447C&#x0003e;G</td><td align="center" valign="top" rowspan="1" colspan="1">E222Q</td><td align="center" valign="top" rowspan="1" colspan="1">Uncertain significance (ClinVar ID: 1163279)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">NOTCH3</td><td align="center" valign="top" rowspan="1" colspan="1">Neurogenic locus notch homolog protein 3</td><td align="center" valign="top" rowspan="1" colspan="1">Notch signaling, promotion of differentiation of progenitor cells into astroglia</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">19:g.15271870G&#x0003e;A</td><td align="center" valign="top" rowspan="1" colspan="1">A2190V</td><td align="center" valign="top" rowspan="1" colspan="1">Benign/Likely benign (ClinVar ID: 803537)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">PRKAR1A</td><td align="center" valign="top" rowspan="1" colspan="1">Protein kinase CAMP&#x02010;dependent Type I Regulatory Subunit Alpha</td><td align="center" valign="top" rowspan="1" colspan="1">Regulatory subunit of the cAMP&#x02010;dependent protein kinase (PKA) complex</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">17:g.66524013G&#x0003e;C</td><td align="center" valign="top" rowspan="1" colspan="1">E247D</td><td align="center" valign="top" rowspan="1" colspan="1">Uncertain significance (ClinVar ID: 1434024)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">FAAP100</td><td align="center" valign="top" rowspan="1" colspan="1">FA Core Complex Associated Protein 100</td><td align="center" valign="top" rowspan="1" colspan="1">DNA damage response pathway</td><td align="center" valign="top" rowspan="1" colspan="1">Missense</td><td align="center" valign="top" rowspan="1" colspan="1">17:g.79514704T&#x0003e;G</td><td align="center" valign="top" rowspan="1" colspan="1">R468S</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table><table-wrap-foot id="pcmr13210-ntgp-0004"><fn id="pcmr13210-note-0005"><label>
<sup>a</sup>
</label><p>HGVS genomic nomenclature indicates the chromosome number, reference sequence (g: genomic), nucleotide position, nucleotide variation (Es. T&#x0003e;G).</p></fn></table-wrap-foot></table-wrap><p>In patient GENIE&#x02010;DFCI&#x02010;202272 (male), both tumors present a frameshift deletion in <italic toggle="yes">BRCA2</italic> gene, namely BRCA2 K1057Tfs*8, which is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic. Standards and guidelines for the interpretation of sequence variants have been published and they recommend the use of specific standard terminology &#x0201c;pathogenic,&#x0201d; &#x0201c;likely pathogenic,&#x0201d; &#x0201c;uncertain significance,&#x0201d; &#x0201c;likely benign,&#x0201d; and &#x0201c;benign&#x0201d; to describe variants identified in genes that cause Mendelian disorders (Richards et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0114" ref-type="bibr">2015</xref>). Moreover, in ClinVar, which is a freely accessible public archive about relationships among variation and human health, this mutation has been described as a pathogenic germline mutation. Specifically, this variation has been associated with breast cancer (Breast Cancer Association Consortium et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0012" ref-type="bibr">2021</xref>; Darst et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0025" ref-type="bibr">2021</xref>). <italic toggle="yes">BRCA2</italic>, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types (Andreassen et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0002" ref-type="bibr">2021</xref>). Germline mutations of <italic toggle="yes">BRCA2</italic> predispose individuals to a high risk of breast and ovarian cancer, and elevated risk of other cancers, including those of the pancreas (Nelson et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0098" ref-type="bibr">2013</xref>; van Asperen et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0133" ref-type="bibr">2005</xref>) and melanoma (Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0063" ref-type="bibr">2019</xref>). Except for <italic toggle="yes">BRCA2</italic> mutation, the biological significance of all the other mutations is still unknown or with an unclear role.</p><p>Both patients present mutation in NOTCH family member, namely <italic toggle="yes">NOTCH1</italic> and <italic toggle="yes">NOTCH3</italic>. For the mutation in <italic toggle="yes">NOTCH1</italic> gene, there are conflicting interpretations of pathogenicity, while for <italic toggle="yes">NOTCH3</italic>, the mutation seems to be benign or likely benign. <italic toggle="yes">NOTCH1</italic> is a transmembrane receptor and transcription factor, and can function as both an oncogene and tumor suppressor. In melanoma, <italic toggle="yes">NOTCH1</italic> promotes melanoma growth, progression (Liu et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0085" ref-type="bibr">2006</xref>) and angiogenesis (Murtas et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0095" ref-type="bibr">2015</xref>), while in pancreatic cancer, <italic toggle="yes">NOTCH1</italic> seems to act as tumor suppressor gene, in fact, the loss of <italic toggle="yes">NOTCH1</italic> resulted in increased tumor incidence and progression (Hanlon et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0050" ref-type="bibr">2010</xref>). <italic toggle="yes">NOTCH3</italic> encodes a Type I transmembrane protein of the NOTCH family, and missense and nonsense mutations in <italic toggle="yes">NOTCH3</italic> have been identified in various cancers. In melanoma, <italic toggle="yes">NOTCH3</italic> activity is associated with enhanced melanoma cell migration, while in pancreatic cancer, high expression of <italic toggle="yes">NOTCH3</italic> is correlated with tumor grade, metastasis, high invasion and poor overall survival rates (Zhou et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0153" ref-type="bibr">2016</xref>).</p><p>
<italic toggle="yes">PDGFRA</italic>, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement, or amplification in a diverse range of cancers. Functional mutations of <italic toggle="yes">PDGFRA</italic> have been described as activator of MAPK and PI3K/AKT pathway in melanoma (Dai et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0023" ref-type="bibr">2020</xref>), while in pancreatic cancer, <italic toggle="yes">PDGFRA</italic> is able to predict immune infiltration and survival outcomes, specifically, high <italic toggle="yes">PDGFRA</italic> expression is associated with increased immune infiltration and prolonged overall survival (Wu et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0147" ref-type="bibr">2022</xref>). In the analyzed patient, the mutation has conflicting interpretations of pathogenicity.</p><p>Mutations in <italic toggle="yes">ASXL1</italic> and <italic toggle="yes">RIF1</italic> gene in patient GENIE&#x02010;DFCI&#x02010;202272 (male) have been not yet described and found in ClinVar. <italic toggle="yes">ASXL1</italic> is a tumor suppressor and epigenetic regulator that affects chromatin remodeling. <italic toggle="yes">ASXL1</italic> is inactivated by mutation in various cancer types, most frequently in myeloid malignancies. However, <italic toggle="yes">ASXL1</italic> results to be highly expressed in metastatic melanoma compared to primary melanoma and associated with poor overall survival in melanoma patients (Chen et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0017" ref-type="bibr">2019</xref>). In a study of familial pancreatic cancer patients, two possibly deleterious germline variants have been detected in <italic toggle="yes">ASXL1</italic> gene (Kasuga et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0068" ref-type="bibr">2022</xref>). <italic toggle="yes">RIF1</italic> is one of the DNA damage repair (DDR) genes, and it has been reported to play significant roles in the DNA damage response and replication timing regulation. In pancreatic cancer, mutations in this gene have been reported (Stoof et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0129" ref-type="bibr">2021</xref>), while in melanoma, this gene has been not yet described.</p><p>From the same family of DNA damage repair genes, there is <italic toggle="yes">FANCA</italic> gene. FANCA is a tumor suppressor and DNA repair protein. Germline mutations of <italic toggle="yes">FANCA</italic> have been associated with the cancer predisposition syndrome Fanconi Anemia. Genetic variants in Fanconi anemia pathway genes, namely <italic toggle="yes">BRCA2</italic> and <italic toggle="yes">FANCA</italic>, could predict melanoma survival (Yin et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0149" ref-type="bibr">2015</xref>). <italic toggle="yes">FANCA</italic> has been also examined as a candidate susceptibility gene for familial pancreatic cancer, but the 12 analyzed germline <italic toggle="yes">FANCA</italic> gene mutations found in 44 patients with familial pancreatic cancer did not contribute to familial pancreatic cancer susceptibility (Rogers et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0117" ref-type="bibr">2004</xref>). Mutation found in GENIE&#x02010;DFCI&#x02010;089908 patient has conflicting interpretations of pathogenicity. Another gene linked to Fanconi anemia pathway is <italic toggle="yes">FAAP100</italic> gene. <italic toggle="yes">FAAP100</italic> seems to be essential for activation of the Fanconi anemia&#x02010;associated DNA damage response pathway (Ling et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0082" ref-type="bibr">2007</xref>). The mutation found in GENIE&#x02010;DFCI&#x02010;089908 patient has never been described in ClinVar and literature about this gene in melanoma and pancreatic cancer is missing.</p><p>GENIE&#x02010;DFCI&#x02010;089908 patient showed other two variations in two genes with uncertain significance, namely in <italic toggle="yes">SBDS</italic>, <italic toggle="yes">PRKAR1A</italic> genes. It was suggesting a role of <italic toggle="yes">SBDS</italic> in the pathogenesis of, or response to, inflammatory and neoplastic pancreatic diseases, including pancreatic cancer (Kayed et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0069" ref-type="bibr">2008</xref>). <italic toggle="yes">PRKAR1A</italic> encodes for a regulatory subunit of protein kinase A and its mutations are associated with Carney complex syndrome and adrenocortical tumors. Carney complex (CNC) is a rare disease associated with multiple neoplasias, including a predisposition to pancreatic tumors; it is caused most frequently by the inactivation of the <italic toggle="yes">PRKAR1A</italic> gene (Saloustros et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0121" ref-type="bibr">2017</xref>). In addition, the protein product of <italic toggle="yes">PRKAR1A</italic> gene can be used as a marker for the identification of specific histological subtypes of cutaneous nevi and CM (Ricci et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0113" ref-type="bibr">2022</xref>).</p><p>Although mutations are known as the most commonly genetic modifications able to cause cancer, genomic alterations such as copy number alterations (CNA), also known as copy number variation (CNV), are also playing an emergent role. CNA refer to a phenomenon in which segments of the genome are repeated or deleted, with varying numbers of these repeats among different individuals' genomes.</p><p>For this reason, in addition to mutated gene, we investigate and compared genes affected by copy number alteration with a frequency of at least 3% in both melanoma and pancreatic cancer (Table&#x000a0;<xref rid="pcmr13210-tbl-0007" ref-type="table">7</xref>).</p><table-wrap position="float" id="pcmr13210-tbl-0007" content-type="TABLE"><label>TABLE 7</label><caption><p>Common copy number alterations (CNA) in melanoma and pancreatic cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description&#x02014;gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pathway</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cytoband</th><th align="center" valign="bottom" rowspan="1" colspan="1">Copy number alteration</th><th align="center" valign="bottom" rowspan="1" colspan="1">Frequency in melanoma</th><th align="center" valign="bottom" rowspan="1" colspan="1">Profiled samples (<italic toggle="yes">n</italic>) in melanoma</th><th align="center" valign="bottom" rowspan="1" colspan="1">Frequency in pancreatic cancer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Profiled samples (<italic toggle="yes">n</italic>) in pancreatic cancer</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CDKN2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin&#x02010;dependent kinase inhibitor 2A</td><td align="center" valign="top" rowspan="1" colspan="1">Cell&#x02010;cycle</td><td align="center" valign="top" rowspan="1" colspan="1">9p21.3</td><td align="center" valign="top" rowspan="1" colspan="1">HOMDEL</td><td align="center" valign="top" rowspan="1" colspan="1">22.1%</td><td align="center" valign="top" rowspan="1" colspan="1">2916</td><td align="center" valign="top" rowspan="1" colspan="1">14.8%</td><td align="center" valign="top" rowspan="1" colspan="1">5959</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDKN2B</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin&#x02010;dependent kinase inhibitor 2B</td><td align="center" valign="top" rowspan="1" colspan="1">Cell&#x02010;cycle</td><td align="center" valign="top" rowspan="1" colspan="1">9p21.3</td><td align="center" valign="top" rowspan="1" colspan="1">HOMDEL</td><td align="center" valign="top" rowspan="1" colspan="1">17.5%</td><td align="center" valign="top" rowspan="1" colspan="1">2881</td><td align="center" valign="top" rowspan="1" colspan="1">13.8%</td><td align="center" valign="top" rowspan="1" colspan="1">5874</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MTAP</td><td align="center" valign="top" rowspan="1" colspan="1">Methylthioadenosine phosphorylase</td><td align="center" valign="top" rowspan="1" colspan="1">Methionine salvage pathway</td><td align="center" valign="top" rowspan="1" colspan="1">9p21.3</td><td align="center" valign="top" rowspan="1" colspan="1">HOMDEL</td><td align="center" valign="top" rowspan="1" colspan="1">9.9%</td><td align="center" valign="top" rowspan="1" colspan="1">1421</td><td align="center" valign="top" rowspan="1" colspan="1">11.0%</td><td align="center" valign="top" rowspan="1" colspan="1">2898</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCND1</td><td align="center" valign="top" rowspan="1" colspan="1">Cyclin D1</td><td align="center" valign="top" rowspan="1" colspan="1">Cell&#x02010;cycle</td><td align="center" valign="top" rowspan="1" colspan="1">11q13.3</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">3.5%</td><td align="center" valign="top" rowspan="1" colspan="1">2911</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FGF3</td><td align="center" valign="top" rowspan="1" colspan="1">Fibroblast growth factor 3</td><td align="center" valign="top" rowspan="1" colspan="1">Negative regulator of bone growth</td><td align="center" valign="top" rowspan="1" colspan="1">11q13.3</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">3.5%</td><td align="center" valign="top" rowspan="1" colspan="1">1844</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FGF4</td><td align="center" valign="top" rowspan="1" colspan="1">Fibroblast growth factor 4</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator in developmental process.</td><td align="center" valign="top" rowspan="1" colspan="1">11q13.3</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">3.6%</td><td align="center" valign="top" rowspan="1" colspan="1">1746</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FGF19</td><td align="center" valign="top" rowspan="1" colspan="1">Fibroblast growth factor 19</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of bile acid synthesis, triglycerides levels, gluconeogenesis, and glycogen and protein synthesis</td><td align="center" valign="top" rowspan="1" colspan="1">11q13.3</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">3.8%</td><td align="center" valign="top" rowspan="1" colspan="1">1844</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GAB2</td><td align="center" valign="top" rowspan="1" colspan="1">GRB2&#x02010;associated&#x02010;binding protein 2</td><td align="center" valign="top" rowspan="1" colspan="1">Activator of PI3K pathway</td><td align="center" valign="top" rowspan="1" colspan="1">11q14</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">3.2%</td><td align="center" valign="top" rowspan="1" colspan="1">475</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSD3B1</td><td align="center" valign="top" rowspan="1" colspan="1">Hydroxy&#x02010;delta&#x02010;5&#x02010;steroid dehydrogenase, 3 beta&#x02010; and steroid delta&#x02010;isomerase 1</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of production of steroid hormones</td><td align="center" valign="top" rowspan="1" colspan="1">1p12</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">3.5%</td><td align="center" valign="top" rowspan="1" colspan="1">227</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PTEN</td><td align="center" valign="top" rowspan="1" colspan="1">Phosphatase and tensin homolog</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of PIP3 signaling</td><td align="center" valign="top" rowspan="1" colspan="1">10q23.31</td><td align="center" valign="top" rowspan="1" colspan="1">HOMDEL</td><td align="center" valign="top" rowspan="1" colspan="1">3.1%</td><td align="center" valign="top" rowspan="1" colspan="1">2916</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PTPN6</td><td align="center" valign="top" rowspan="1" colspan="1">Protein tyrosine phosphatase non&#x02010;receptor type 6</td><td align="center" valign="top" rowspan="1" colspan="1">Regulator of PIP3 signaling</td><td align="center" valign="top" rowspan="1" colspan="1">12p13.31</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">100%</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MYC</td><td align="center" valign="top" rowspan="1" colspan="1">MYC proto&#x02010;oncogene</td><td align="center" valign="top" rowspan="1" colspan="1">Regulates the expression of genes involved in cell&#x02010;cycle control</td><td align="center" valign="top" rowspan="1" colspan="1">8q24.21</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">3.2%</td><td align="center" valign="top" rowspan="1" colspan="1">5959</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SMAD4</td><td align="center" valign="top" rowspan="1" colspan="1">SMAD family member 4</td><td align="center" valign="top" rowspan="1" colspan="1">Member of TGF&#x02010;&#x003b2;1/SMAD4 signaling pathway</td><td align="center" valign="top" rowspan="1" colspan="1">18q21.2</td><td align="center" valign="top" rowspan="1" colspan="1">HOMDEL</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">4.2%</td><td align="center" valign="top" rowspan="1" colspan="1">5960</td></tr></tbody></table><table-wrap-foot id="pcmr13210-ntgp-0005"><fn id="pcmr13210-note-0006"><p>Abbreviations: AMP, amplification; HOMDEL, homozygous deletion.</p></fn></table-wrap-foot></table-wrap><p>In melanoma samples, we found 11 CNA, while in pancreatic cancer, we detected five CNA. The three common CNA in both melanoma and pancreatic cancer are <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">CDKN2B</italic>, and <italic toggle="yes">MTAP</italic>, which are homozygous deleted and located in the same locus, namely 9p21. Chr9p22.1&#x02010;21.3 locus deletions have already been related to the development of several types of cancer, especially due to the presence of <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">CDKN2B</italic> genes (Goncalves, Reis, and Bidinotto&#x000a0;<xref rid="pcmr13210-bib-0048" ref-type="bibr">2022</xref>). <italic toggle="yes">CDKN2B</italic> is considered a tumor suppressor and encodes a cyclin&#x02010;dependent kinase inhibitor that regulates cell growth and the cell cycle G1 progression by preventing the activation of cyclin&#x02010;D&#x02010;dependent kinases. In various tumors, <italic toggle="yes">CDKN2B</italic> has been found to be frequently co&#x02010;deleted with the neighboring tumor suppressor gene <italic toggle="yes">CDKN2A</italic>. <italic toggle="yes">CDKN2B</italic> deletion has been reported in a significantly high proportion in pancreatic cancer (Oketch, Giulietti, and Piva&#x000a0;<xref rid="pcmr13210-bib-0100" ref-type="bibr">2023</xref>) and in melanoma (McNeal et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0091" ref-type="bibr">2015</xref>). In addition of <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">CDKN2B</italic>, there are several other genes in the region with potential importance in tumorigenesis, such as <italic toggle="yes">MTAP</italic>, which results to be homozygous deleted. In melanoma, the loss of <italic toggle="yes">MTAP</italic> was shown to have an effect on tumor invasion and metastasis. In addition, the loss of MTAP results in an inhibition of STAT signaling pathways regulated by interferon, which to ineffectiveness of interferon therapy (Wild et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0142" ref-type="bibr">2007</xref>). In pancreatic cancer, it has been observed that MTAP deficiency drives tumor progression by inducing metabolic reprogramming, providing a novel target and therapeutic strategy for treating MTAP&#x02010;deficient disease (Hu et&#x000a0;al.&#x000a0;<xref rid="pcmr13210-bib-0060" ref-type="bibr">2021</xref>).</p></sec><sec sec-type="conclusions" id="pcmr13210-sec-0005"><label>5</label><title>Conclusion</title><p>To date, it is known that familial melanoma and pancreatic cancer can be associated with an inheritance pattern of germline mutations in predisposing genes. This study contributes valuable insights into the genetic underpinnings of melanoma and pancreatic cancer, urging the continued exploration and research of new genetic biomarkers able to identify patients at high risk of developing both cancers. Understanding association between cancer risk and gene mutations is of great help for clinicians involved in cancer screening: It can guide the clinician in performing appropriate genetic testing and surveillance in these families. Mutations in the <italic toggle="yes">CDKN2A</italic> gene present the most prevalent genetic cause of increased susceptibility to the development of both melanoma and pancreatic cancer. Other genes found in literature and in open&#x02010;access resources have been described; however, their role driving or predisposing both tumors still need to be investigated. A larger sample of patients and families with both melanoma and pancreatic cancer needs to be studied in order to find new candidates predisposing to the occurrence of these cancers.</p><p>All members of families with combined occurrence of pancreatic cancer and melanoma should be counseled and offered screening for <italic toggle="yes">CDKN2A</italic> mutations to identify high&#x02010;risk family members who should be enrolled in a clinical screening program. In future, the identification of individuals with a pathogenic gene variant in <italic toggle="yes">CDKN2A</italic> gene or in other genes will hold significance for screening at&#x02010;risk relatives and devising an effective clinical strategy for the patient.</p></sec><sec id="pcmr13210-sec-0006"><title>Author Contributions</title><p>Conception and design: Elisabetta Broseghini, Federico Venturi, Manuela Ferracin, Emi Dika. Acquisition of data: Elisabetta Broseghini, Federico Venturi. Analysis and interpretation of data: Elisabetta Broseghini, Federico Venturi, Giulia Veronesi, Biagio Scotti, Marina Migliori, Desy Marini, Claudio Ricci, Riccardo Casadei, Manuela Ferracin, Emi Dika. Drafting of the manuscript: Elisabetta Broseghini, Federico Venturi, Emi Dika. Critical revision of the manuscript for important intellectual content: Manuela Ferracin, Emi Dika. All authors reviewed the results and approved the final version of the manuscript.</p></sec><sec sec-type="COI-statement" id="pcmr13210-sec-0007"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pcmr13210-supitem-0001" position="float" content-type="local-data"><caption><p>
Table&#x000a0;S1.
</p></caption><media xlink:href="PCMR-38-0-s002.docx"/></supplementary-material><supplementary-material id="pcmr13210-supitem-0002" position="float" content-type="local-data"><caption><p>
Table&#x000a0;S2.
</p></caption><media xlink:href="PCMR-38-0-s001.docx"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="pcmr13210-sec-0009"><title>Data Availability Statement</title><p>The authors have nothing to report.</p></sec><ref-list content-type="cited-references" id="pcmr13210-bibl-0001"><title>References</title><ref id="pcmr13210-bib-0001"><mixed-citation publication-type="journal" id="pcmr13210-cit-0001">
<string-name>
<surname>Abe</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kitago</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Kitagawa</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Hirasawa</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Hereditary Pancreatic Cancer</article-title>.&#x0201d; <source>International Journal of Clinical Oncology</source>
<volume>26</volume>: <fpage>1784</fpage>&#x02013;<lpage>1792</lpage>. <pub-id pub-id-type="doi">10.1007/s10147-021-02015-6</pub-id>.<pub-id pub-id-type="pmid">34476650</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0002"><mixed-citation publication-type="journal" id="pcmr13210-cit-0002">
<string-name>
<surname>Andreassen</surname>, <given-names>P. R.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Seo</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Wiek</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Hanenberg</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Understanding BRCA2 Function as a Tumor Suppressor Based on Domain&#x02010;Specific Activities in DNA Damage Responses</article-title>.&#x0201d; <source>Genes (Basel)</source>
<volume>12</volume>: 1034. <pub-id pub-id-type="doi">10.3390/genes12071034</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0003"><mixed-citation publication-type="journal" id="pcmr13210-cit-0003">
<string-name>
<surname>Aoude</surname>, <given-names>L. G.</given-names>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Pritchard</surname>
</string-name>, <string-name>
<given-names>C. D.</given-names>
<surname>Robles&#x02010;Espinoza</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma</article-title>.&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>107</volume>: dju408. <pub-id pub-id-type="doi">10.1093/jnci/dju408</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0004"><mixed-citation publication-type="journal" id="pcmr13210-cit-0004">
<string-name>
<surname>Aoude</surname>, <given-names>L. G.</given-names>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Wadt</surname>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Pritchard</surname>
</string-name>, and <string-name>
<given-names>N. K.</given-names>
<surname>Hayward</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>Genetics of Familial Melanoma: 20&#x02009;Years After CDKN2A</article-title>.&#x0201d; <source>Pigment Cell &#x00026; Melanoma Research</source>
<volume>28</volume>: <fpage>148</fpage>&#x02013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1111/pcmr.12333</pub-id>.<pub-id pub-id-type="pmid">25431349</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0005"><mixed-citation publication-type="journal" id="pcmr13210-cit-0005">
<string-name>
<surname>Aung</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<given-names>S. E.</given-names>
<surname>Fischer</surname>
</string-name>, <string-name>
<given-names>R. E.</given-names>
<surname>Denroche</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Genomics&#x02010;Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results From the COMPASS Trial</article-title>.&#x0201d; <source>Clinical Cancer Research</source>
<volume>24</volume>: <fpage>1344</fpage>&#x02013;<lpage>1354</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2994</pub-id>.<pub-id pub-id-type="pmid">29288237</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0006"><mixed-citation publication-type="journal" id="pcmr13210-cit-0006">
<string-name>
<surname>Azin</surname>, <given-names>M.</given-names>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Demehri</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>STK11 Loss: A Novel Mechanism for Melanoma Metastasis With Therapeutic Implications</article-title>.&#x0201d; <source>Journal of Investigative Dermatology</source>
<volume>142</volume>: <fpage>1007</fpage>&#x02013;<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2021.10.003</pub-id>.<pub-id pub-id-type="pmid">35131083</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0007"><mixed-citation publication-type="journal" id="pcmr13210-cit-0007">
<string-name>
<surname>Bartsch</surname>, <given-names>D. K.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sina&#x02010;Frey</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Lang</surname>
</string-name>, et&#x000a0;al. <year>2002</year>. &#x0201c;<article-title>CDKN2A Germline Mutations in Familial Pancreatic Cancer</article-title>.&#x0201d; <source>Annals of Surgery</source>
<volume>236</volume>: <fpage>730</fpage>&#x02013;<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1097/00000658-200212000-00005</pub-id>.<pub-id pub-id-type="pmid">12454511</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0008"><mixed-citation publication-type="journal" id="pcmr13210-cit-0008">
<string-name>
<surname>Berger</surname>, <given-names>M. F.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Hodis</surname>
</string-name>, <string-name>
<given-names>T. P.</given-names>
<surname>Heffernan</surname>
</string-name>, et&#x000a0;al. <year>2012</year>. &#x0201c;<article-title>Melanoma Genome Sequencing Reveals Frequent PREX2 Mutations</article-title>.&#x0201d; <source>Nature</source>
<volume>485</volume>: <fpage>502</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1038/nature11071</pub-id>.<pub-id pub-id-type="pmid">22622578</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0009"><mixed-citation publication-type="journal" id="pcmr13210-cit-0009">
<string-name>
<surname>Bertolotto</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Lesueur</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Giuliano</surname>
</string-name>, et&#x000a0;al. <year>2011</year>. &#x0201c;<article-title>A SUMOylation&#x02010;Defective MITF Germline Mutation Predisposes to Melanoma and Renal Carcinoma</article-title>.&#x0201d; <source>Nature</source>
<volume>480</volume>: <fpage>94</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/nature10539</pub-id>.<pub-id pub-id-type="pmid">22012259</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0010"><mixed-citation publication-type="journal" id="pcmr13210-cit-0010">
<string-name>
<surname>Birnbaum</surname>, <given-names>D. J.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Adelaide</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Mamessier</surname>
</string-name>, et&#x000a0;al. <year>2011</year>. &#x0201c;<article-title>Genome Profiling of Pancreatic Adenocarcinoma</article-title>.&#x0201d; <source>Genes, Chromosomes &#x00026; Cancer</source>
<volume>50</volume>: <fpage>456</fpage>&#x02013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.20870</pub-id>.<pub-id pub-id-type="pmid">21412932</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0011"><mixed-citation publication-type="journal" id="pcmr13210-cit-0011">
<string-name>
<surname>Borja</surname>, <given-names>N. A.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Silva&#x02010;Smith</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Parekh</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Sussman</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Tekin</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Atypical ATMs: Broadening the Phenotypic Spectrum of ATM&#x02010;Associated Hereditary cancer</article-title>.&#x0201d; <source>Frontiers in Oncology</source>
<volume>13</volume>: <elocation-id>1068110</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1068110</pub-id>.<pub-id pub-id-type="pmid">36865800</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0012"><mixed-citation publication-type="journal" id="pcmr13210-cit-0012">
<collab collab-type="authors">Breast Cancer Association Consortium</collab>
, <string-name>
<given-names>L.</given-names>
<surname>Dorling</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Carvalho</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Breast Cancer Risk Genes&#x02014;Association Analysis in More Than 113,000 Women</article-title>.&#x0201d; <source>New England Journal of Medicine</source>
<volume>384</volume>: <fpage>428</fpage>&#x02013;<lpage>439</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1913948</pub-id>.<pub-id pub-id-type="pmid">33471991</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0013"><mixed-citation publication-type="journal" id="pcmr13210-cit-0013">
<string-name>
<surname>Broseghini</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Londin</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ferracin</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>MicroRNA Isoforms Contribution to Melanoma Pathogenesis</article-title>.&#x0201d; <source>Noncoding RNA</source>
<volume>7: 63</volume>. <pub-id pub-id-type="doi">10.3390/ncrna7040063</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0014"><mixed-citation publication-type="journal" id="pcmr13210-cit-0014">
<string-name>
<surname>Campos</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Fragoso</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Luis</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>High&#x02010;Throughput Sequencing Identifies 3 Novel Susceptibility Genes for Hereditary Melanoma</article-title>.&#x0201d; <source>Genes (Basel)</source>
<volume>11</volume>: 403. <pub-id pub-id-type="doi">10.3390/genes11040403</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0015"><mixed-citation publication-type="journal" id="pcmr13210-cit-0015">
<collab collab-type="authors">Cancer Genome Atlas Network</collab>
. <year>2015</year>. &#x0201c;<article-title>Genomic Classification of Cutaneous Melanoma</article-title>.&#x0201d; <source>Cell</source>
<volume>161</volume>: <fpage>1681</fpage>&#x02013;<lpage>1696</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.05.044</pub-id>.<pub-id pub-id-type="pmid">26091043</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0016"><mixed-citation publication-type="journal" id="pcmr13210-cit-0016">
<string-name>
<surname>Carvajal</surname>, <given-names>R. D.</given-names>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Lawrence</surname>
</string-name>, <string-name>
<given-names>J. S.</given-names>
<surname>Weber</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition</article-title>.&#x0201d; <source>Clinical Cancer Research</source>
<volume>21</volume>: <fpage>2289</fpage>&#x02013;<lpage>2296</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1630</pub-id>.<pub-id pub-id-type="pmid">25695690</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0017"><mixed-citation publication-type="journal" id="pcmr13210-cit-0017">
<string-name>
<surname>Chen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Shi</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Identification of Key Candidate Genes Involved in Melanoma Metastasis</article-title>.&#x0201d; <source>Molecular Medicine Reports</source>
<volume>20</volume>: <fpage>903</fpage>&#x02013;<lpage>914</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2019.10314</pub-id>.<pub-id pub-id-type="pmid">31173190</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0018"><mixed-citation publication-type="journal" id="pcmr13210-cit-0018">
<string-name>
<surname>Ciccarese</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Dalmasso</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Bruno</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Clinical, Pathological and Dermoscopic Phenotype of MITF p.E318K Carrier Cutaneous Melanoma Patients</article-title>.&#x0201d; <source>Journal of Translational Medicine</source>
<volume>18</volume>: <fpage>78</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-020-02253-8</pub-id>.<pub-id pub-id-type="pmid">32054529</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0019"><mixed-citation publication-type="journal" id="pcmr13210-cit-0019">
<string-name>
<surname>Cicenas</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kvederaviciute</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Meskinyte</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Meskinyte&#x02010;Kausiliene</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Skeberdyte</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Cicenas</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer</article-title>.&#x0201d; <source>Cancers (Basel)</source>
<volume>9</volume>: <elocation-id>42</elocation-id>. <pub-id pub-id-type="doi">10.3390/cancers9050042</pub-id>.<pub-id pub-id-type="pmid">28452926</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0020"><mixed-citation publication-type="journal" id="pcmr13210-cit-0020">
<string-name>
<surname>Clark</surname>, <given-names>W. H.</given-names>, <suffix>Jr.</suffix>
</string-name>, <string-name>
<given-names>R. R.</given-names>
<surname>Reimer</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Greene</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Ainsworth</surname>
</string-name>, and <string-name>
<given-names>M. J.</given-names>
<surname>Mastrangelo</surname>
</string-name>. <year>1978</year>. &#x0201c;<article-title>Origin of Familial Malignant Melanomas From Heritable Melanocytic Lesions. &#x02018;The B&#x02010;K Mole syndrome&#x02019;</article-title>.&#x0201d; <source>Archives of Dermatology</source>
<volume>114</volume>: <fpage>732</fpage>&#x02013;<lpage>738</lpage>.<pub-id pub-id-type="pmid">646394</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0021"><mixed-citation publication-type="journal" id="pcmr13210-cit-0021">
<string-name>
<surname>Cotterchio</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Lowcock</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Bider&#x02010;Canfield</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Association Between Variants in Atopy&#x02010;Related Immunologic Candidate Genes and Pancreatic Cancer Risk</article-title>.&#x0201d; <source>PLoS One</source>
<volume>10</volume>: <elocation-id>e0125273</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0125273</pub-id>.<pub-id pub-id-type="pmid">25945796</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0022"><mixed-citation publication-type="journal" id="pcmr13210-cit-0022">
<string-name>
<surname>Curtin</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Busam</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Pinkel</surname>
</string-name>, and <string-name>
<given-names>B. C.</given-names>
<surname>Bastian</surname>
</string-name>. <year>2006</year>. &#x0201c;<article-title>Somatic Activation of KIT in Distinct Subtypes of Melanoma</article-title>.&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>24</volume>: <fpage>4340</fpage>&#x02013;<lpage>4346</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2006.06.2984</pub-id>.<pub-id pub-id-type="pmid">16908931</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0023"><mixed-citation publication-type="journal" id="pcmr13210-cit-0023">
<string-name>
<surname>Dai</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Xu</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>A Functional Synonymous Variant in PDGFRA Is Associated With Better Survival in Acral Melanoma</article-title>.&#x0201d; <source>Journal of Cancer</source>
<volume>11</volume>: <fpage>2945</fpage>&#x02013;<lpage>2956</lpage>. <pub-id pub-id-type="doi">10.7150/jca.43010</pub-id>.<pub-id pub-id-type="pmid">32226509</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0024"><mixed-citation publication-type="journal" id="pcmr13210-cit-0024">
<string-name>
<surname>Danishevich</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Bilyalov</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Nikolaev</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes</article-title>.&#x0201d; <source>Biomedicine</source>
<volume>11</volume>: 3343. <pub-id pub-id-type="doi">10.3390/biomedicines11123343</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0025"><mixed-citation publication-type="journal" id="pcmr13210-cit-0025">
<string-name>
<surname>Darst</surname>, <given-names>B. F.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Dadaev</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Saunders</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer</article-title>.&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>113</volume>: <fpage>616</fpage>&#x02013;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djaa132</pub-id>.<pub-id pub-id-type="pmid">32853339</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0026"><mixed-citation publication-type="journal" id="pcmr13210-cit-0026">
<string-name>
<surname>Dawkins</surname>, <given-names>J. B.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Maniati</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates With Improved Outcome in Pancreatic Ductal Adenocarcinoma</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>76</volume>: <fpage>4861</fpage>&#x02013;<lpage>4871</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-0481</pub-id>.<pub-id pub-id-type="pmid">27280393</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0027"><mixed-citation publication-type="journal" id="pcmr13210-cit-0027">
<string-name>
<surname>de Andrade</surname>, <given-names>K. C.</given-names>
</string-name>, <string-name>
<given-names>M. N.</given-names>
<surname>Frone</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Wegman&#x02010;Ostrosky</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Variable Population Prevalence Estimates of Germline TP53 Variants: A gnomAD&#x02010;Based Analysis</article-title>.&#x0201d; <source>Human Mutation</source>
<volume>40</volume>: <fpage>97</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1002/humu.23673</pub-id>.<pub-id pub-id-type="pmid">30352134</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0028"><mixed-citation publication-type="journal" id="pcmr13210-cit-0028">
<string-name>
<surname>De Bosscher</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>C. S.</given-names>
<surname>Hill</surname>
</string-name>, and <string-name>
<given-names>F. J.</given-names>
<surname>Nicolas</surname>
</string-name>. <year>2004</year>. &#x0201c;<article-title>Molecular and Functional Consequences of Smad4 C&#x02010;Terminal Missense Mutations in Colorectal Tumour Cells</article-title>.&#x0201d; <source>Biochemical Journal</source>
<volume>379</volume>: <fpage>209</fpage>&#x02013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20031886</pub-id>.<pub-id pub-id-type="pmid">14715079</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0029"><mixed-citation publication-type="journal" id="pcmr13210-cit-0029">
<string-name>
<surname>de Snoo</surname>, <given-names>F. A.</given-names>
</string-name>, <string-name>
<given-names>D. T.</given-names>
<surname>Bishop</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Bergman</surname>
</string-name>, et&#x000a0;al. <year>2008</year>. &#x0201c;<article-title>Increased Risk of cancer Other Than Melanoma in CDKN2A Founder Mutation (p16&#x02010;Leiden)&#x02010;positive Melanoma Families</article-title>.&#x0201d; <source>Clinical Cancer Research</source>
<volume>14</volume>: <fpage>7151</fpage>&#x02013;<lpage>7157</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0403</pub-id>.<pub-id pub-id-type="pmid">18981015</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0030"><mixed-citation publication-type="journal" id="pcmr13210-cit-0030">
<string-name>
<surname>Dika</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Broseghini</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Porcellini</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Unraveling the Role of microRNA/isomiR Network in Multiple Primary Melanoma Pathogenesis</article-title>.&#x0201d; <source>Cell Death &#x00026; Disease</source>
<volume>12</volume>: <fpage>473</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-021-03764-y</pub-id>.<pub-id pub-id-type="pmid">33980826</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0031"><mixed-citation publication-type="journal" id="pcmr13210-cit-0031">
<string-name>
<surname>Dika</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Patrizi</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Rossi</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Clinical Histopathological Features and CDKN2A/CDK4/MITF Mutational Status of Patients With Multiple Primary Melanomas From Bologna: Italy Is a Fascinating but Complex Mosaic</article-title>.&#x0201d; <source>Italian Journal of Dermatology and Venereology</source>
<volume>156</volume>: <fpage>599</fpage>&#x02013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.23736/S2784-8671.20.06496-2</pub-id>.<pub-id pub-id-type="pmid">32221274</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0032"><mixed-citation publication-type="journal" id="pcmr13210-cit-0032">
<string-name>
<surname>Dika</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Riefolo</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Porcellini</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma</article-title>.&#x0201d; <source>Journal of Investigative Dermatology</source>
<volume>140</volume>: <fpage>2260</fpage>&#x02013;<lpage>2267</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2020.03.949</pub-id>.<pub-id pub-id-type="pmid">32275975</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0033"><mixed-citation publication-type="journal" id="pcmr13210-cit-0033">
<string-name>
<surname>Dika</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Veronesi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Altimari</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients</article-title>.&#x0201d; <source>American Journal of Clinical Pathology</source>
<volume>153</volume>: <fpage>664</fpage>&#x02013;<lpage>671</lpage>. <pub-id pub-id-type="doi">10.1093/ajcp/aqz209</pub-id>.<pub-id pub-id-type="pmid">32017841</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0034"><mixed-citation publication-type="journal" id="pcmr13210-cit-0034">
<string-name>
<surname>Ding</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Xing</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Dai</surname>
</string-name>. <year>2020</year>. &#x0201c;<article-title>Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising</article-title>.&#x0201d; <source>Journal of Oncology</source>
<volume>2020</volume>: <elocation-id>2845906</elocation-id>. <pub-id pub-id-type="doi">10.1155/2020/2845906</pub-id>.<pub-id pub-id-type="pmid">32670371</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0035"><mixed-citation publication-type="journal" id="pcmr13210-cit-0035">
<string-name>
<surname>Ding</surname>, <given-names>J. T.</given-names>
</string-name>, <string-name>
<given-names>X. T.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>J. H.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>D. Z.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Guo</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>A Pan&#x02010;Cancer Analysis Revealing the Dual Roles of Lysine (K)&#x02010;specific Demethylase 6B in Tumorigenesis and Immunity</article-title>.&#x0201d; <source>Frontiers in Genetics</source>
<volume>13</volume>: <elocation-id>912003</elocation-id>. <pub-id pub-id-type="doi">10.3389/fgene.2022.912003</pub-id>.<pub-id pub-id-type="pmid">35783266</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0036"><mixed-citation publication-type="journal" id="pcmr13210-cit-0036">
<string-name>
<surname>Durante</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Broseghini</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Comito</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Circulating microRNA Biomarkers in Melanoma and Non&#x02010;melanoma Skin cancer</article-title>.&#x0201d; <source>Expert Review of Molecular Diagnostics</source>
<volume>22</volume>: <fpage>305</fpage>&#x02013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1080/14737159.2022.2049243</pub-id>.<pub-id pub-id-type="pmid">35235479</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0037"><mixed-citation publication-type="journal" id="pcmr13210-cit-0037">
<string-name>
<surname>Durante</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Comito</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lambertini</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Broseghini</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ferracin</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Non&#x02010;coding RNA Dysregulation in Skin Cancers</article-title>.&#x0201d; <source>Essays in Biochemistry</source>
<volume>65</volume>: <fpage>641</fpage>&#x02013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1042/EBC20200048</pub-id>.<pub-id pub-id-type="pmid">34414406</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0038"><mixed-citation publication-type="journal" id="pcmr13210-cit-0038">
<string-name>
<surname>Dutton&#x02010;Regester</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Gartner</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Emmanuel</surname>
</string-name>, et&#x000a0;al. <year>2014</year>. &#x0201c;<article-title>A Highly Recurrent RPS27 5'UTR Mutation in Melanoma</article-title>.&#x0201d; <source>Oncotarget</source>
<volume>5</volume>: <fpage>2912</fpage>&#x02013;<lpage>2917</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2048</pub-id>.<pub-id pub-id-type="pmid">24913145</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0039"><mixed-citation publication-type="journal" id="pcmr13210-cit-0039">
<string-name>
<surname>Dzung</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Saltari</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Tiso</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Lyck</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Dummer</surname>
</string-name>, and <string-name>
<given-names>M. P.</given-names>
<surname>Levesque</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>STK11 Prevents Invasion Through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma</article-title>.&#x0201d; <source>Journal of Investigative Dermatology</source>
<volume>142</volume>: <fpage>1171</fpage>&#x02013;<lpage>1182</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2021.09.035</pub-id>.<pub-id pub-id-type="pmid">34757069</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0040"><mixed-citation publication-type="journal" id="pcmr13210-cit-0040">
<string-name>
<surname>Fontana</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Gallerani</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Salamon</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Pace</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Roncarati</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ferracin</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>ARID1A in cancer: Friend or Foe?</article-title>&#x0201d; <source>Frontiers in Oncology</source>
<volume>13</volume>: <elocation-id>1136248</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1136248</pub-id>.<pub-id pub-id-type="pmid">36890819</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0041"><mixed-citation publication-type="journal" id="pcmr13210-cit-0041">
<string-name>
<surname>Friedenson</surname>, <given-names>B.</given-names>
</string-name>
<year>2005</year>. &#x0201c;<article-title>BRCA1 and BRCA2 Pathways and the Risk of Cancers Other Than Breast or Ovarian</article-title>.&#x0201d; <source>MedGenMed</source>
<volume>7</volume>: <fpage>60</fpage>.</mixed-citation></ref><ref id="pcmr13210-bib-0042"><mixed-citation publication-type="journal" id="pcmr13210-cit-0042">
<string-name>
<surname>Froimchuk</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Jang</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Ge</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>Histone H3 Lysine 4 Methyltransferase KMT2D</article-title>.&#x0201d; <source>Gene</source>
<volume>627</volume>: <fpage>337</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2017.06.056</pub-id>.<pub-id pub-id-type="pmid">28669924</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0043"><mixed-citation publication-type="journal" id="pcmr13210-cit-0043">
<string-name>
<surname>Garraway</surname>, <given-names>L. A.</given-names>
</string-name>, and <string-name>
<given-names>W. R.</given-names>
<surname>Sellers</surname>
</string-name>. <year>2006</year>. &#x0201c;<article-title>Lineage Dependency and Lineage&#x02010;Survival Oncogenes in Human cancer</article-title>.&#x0201d; <source>Nature Reviews. Cancer</source>
<volume>6</volume>: <fpage>593</fpage>&#x02013;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1947</pub-id>.<pub-id pub-id-type="pmid">16862190</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0044"><mixed-citation publication-type="journal" id="pcmr13210-cit-0044">
<string-name>
<surname>Garraway</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<given-names>H. R.</given-names>
<surname>Widlund</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Rubin</surname>
</string-name>, et&#x000a0;al. <year>2005</year>. &#x0201c;<article-title>Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma</article-title>.&#x0201d; <source>Nature</source>
<volume>436</volume>: <fpage>117</fpage>&#x02013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1038/nature03664</pub-id>.<pub-id pub-id-type="pmid">16001072</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0045"><mixed-citation publication-type="journal" id="pcmr13210-cit-0045">
<string-name>
<surname>Gershenwald</surname>, <given-names>J. E.</given-names>
</string-name>, and <string-name>
<given-names>R. A.</given-names>
<surname>Scolyer</surname>
</string-name>. <year>2018</year>. &#x0201c;<article-title>Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond</article-title>.&#x0201d; <source>Annals of Surgical Oncology</source>
<volume>25</volume>: <fpage>2105</fpage>&#x02013;<lpage>2110</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-018-6513-7</pub-id>.<pub-id pub-id-type="pmid">29850954</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0046"><mixed-citation publication-type="journal" id="pcmr13210-cit-0046">
<string-name>
<surname>Giardiello</surname>, <given-names>F. M.</given-names>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Brensinger</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Tersmette</surname>
</string-name>, et&#x000a0;al. <year>2000</year>. &#x0201c;<article-title>Very High Risk of Cancer in Familial Peutz&#x02010;Jeghers Syndrome</article-title>.&#x0201d; <source>Gastroenterology</source>
<volume>119</volume>: <fpage>1447</fpage>&#x02013;<lpage>1453</lpage>. <pub-id pub-id-type="doi">10.1053/gast.2000.20228</pub-id>.<pub-id pub-id-type="pmid">11113065</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0047"><mixed-citation publication-type="journal" id="pcmr13210-cit-0047">
<string-name>
<surname>Goldstein</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Chan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Harland</surname>
</string-name>, et&#x000a0;al. <year>2006</year>. &#x0201c;<article-title>High&#x02010;Risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma Across GenoMEL</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>66</volume>: <fpage>9818</fpage>&#x02013;<lpage>9828</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0494</pub-id>.<pub-id pub-id-type="pmid">17047042</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0048"><mixed-citation publication-type="journal" id="pcmr13210-cit-0048">
<string-name>
<surname>Goncalves</surname>, <given-names>P. G.</given-names>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Reis</surname>
</string-name>, and <string-name>
<given-names>L. T.</given-names>
<surname>Bidinotto</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>Significance of Chr9p22.1&#x02010;p21.3 Deletion in Cancer Development: A Pan&#x02010;cancer in Silico Analysis</article-title>.&#x0201d; <source>Anticancer Research</source>
<volume>42</volume>: <fpage>5291</fpage>&#x02013;<lpage>5304</lpage>. <pub-id pub-id-type="doi">10.21873/anticanres.16036</pub-id>.<pub-id pub-id-type="pmid">36288884</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0049"><mixed-citation publication-type="journal" id="pcmr13210-cit-0049">
<string-name>
<surname>Griewank</surname>, <given-names>K. G.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Murali</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Puig&#x02010;Butille</surname>
</string-name>, et&#x000a0;al. <year>2014</year>. &#x0201c;<article-title>TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma</article-title>.&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>106</volume>: dju246. <pub-id pub-id-type="doi">10.1093/jnci/dju246</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0050"><mixed-citation publication-type="journal" id="pcmr13210-cit-0050">
<string-name>
<surname>Hanlon</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Avila</surname>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Demarest</surname>
</string-name>, et&#x000a0;al. <year>2010</year>. &#x0201c;<article-title>Notch1 Functions as a Tumor Suppressor in a Model of K&#x02010;Ras&#x02010;Induced Pancreatic Ductal Adenocarcinoma</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>70</volume>: <fpage>4280</fpage>&#x02013;<lpage>4286</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4645</pub-id>.<pub-id pub-id-type="pmid">20484026</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0051"><mixed-citation publication-type="journal" id="pcmr13210-cit-0051">
<string-name>
<surname>Harland</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>A. E.</given-names>
<surname>Cust</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Badenas</surname>
</string-name>, et&#x000a0;al. <year>2014</year>. &#x0201c;<article-title>Prevalence and Predictors of Germline CDKN2A Mutations for Melanoma Cases From Australia, Spain and the United Kingdom</article-title>.&#x0201d; <source>Hereditary Cancer in Clinical Practice</source>
<volume>12</volume>: <elocation-id>20</elocation-id>. <pub-id pub-id-type="doi">10.1186/1897-4287-12-20</pub-id>.<pub-id pub-id-type="pmid">25780468</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0052"><mixed-citation publication-type="journal" id="pcmr13210-cit-0052">
<string-name>
<surname>Harland</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Petljak</surname>
</string-name>, <string-name>
<given-names>C. D.</given-names>
<surname>Robles&#x02010;Espinoza</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Germline TERT Promoter Mutations Are Rare in Familial Melanoma</article-title>.&#x0201d; <source>Familial Cancer</source>
<volume>15</volume>: <fpage>139</fpage>&#x02013;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-015-9841-9</pub-id>.<pub-id pub-id-type="pmid">26433962</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0053"><mixed-citation publication-type="journal" id="pcmr13210-cit-0053">
<string-name>
<surname>Hawryluk</surname>, <given-names>E. B.</given-names>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Tsao</surname>
</string-name>. <year>2014</year>. &#x0201c;<article-title>Melanoma: Clinical Features and Genomic Insights</article-title>.&#x0201d; <source>Cold Spring Harbor Perspectives in Medicine</source>
<volume>4</volume>: <elocation-id>a015388</elocation-id>. <pub-id pub-id-type="doi">10.1101/cshperspect.a015388</pub-id>.<pub-id pub-id-type="pmid">25183853</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0054"><mixed-citation publication-type="journal" id="pcmr13210-cit-0054">
<string-name>
<surname>Hayashi</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kohno</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Ueno</surname>
</string-name>, et&#x000a0;al. <year>2017</year>. &#x0201c;<article-title>Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer</article-title>.&#x0201d; <source>Pancreas</source>
<volume>46</volume>: <fpage>335</fpage>&#x02013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1097/MPA.0000000000000760</pub-id>.<pub-id pub-id-type="pmid">28099251</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0055"><mixed-citation publication-type="journal" id="pcmr13210-cit-0055">
<string-name>
<surname>Helgadottir</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Ghiorzo</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>van Doorn</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Efficacy of Novel Immunotherapy Regimens in Patients With Metastatic Melanoma With Germline CDKN2A Mutations</article-title>.&#x0201d; <source>Journal of Medical Genetics</source>
<volume>57</volume>: <fpage>316</fpage>&#x02013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2018-105610</pub-id>.<pub-id pub-id-type="pmid">30291219</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0056"><mixed-citation publication-type="journal" id="pcmr13210-cit-0056">
<string-name>
<surname>Helgadottir</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Tuominen</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Olsson</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Hansson</surname>
</string-name>, and <string-name>
<given-names>V.</given-names>
<surname>Hoiom</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>Cancer Risks and Survival in Patients With Multiple Primary Melanomas: Association With Family History of Melanoma and Germline CDKN2A Mutation Status</article-title>.&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>77</volume>: <fpage>893</fpage>&#x02013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2017.05.050</pub-id>.<pub-id pub-id-type="pmid">28818438</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0057"><mixed-citation publication-type="journal" id="pcmr13210-cit-0057">
<string-name>
<surname>Horn</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Figl</surname>
</string-name>, <string-name>
<given-names>P. S.</given-names>
<surname>Rachakonda</surname>
</string-name>, et&#x000a0;al. <year>2013</year>. &#x0201c;<article-title>TERT Promoter Mutations in Familial and Sporadic Melanoma</article-title>.&#x0201d; <source>Science</source>
<volume>339</volume>: <fpage>959</fpage>&#x02013;<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1126/science.1230062</pub-id>.<pub-id pub-id-type="pmid">23348503</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0058"><mixed-citation publication-type="journal" id="pcmr13210-cit-0058">
<string-name>
<surname>Hsu</surname>, <given-names>F. C.</given-names>
</string-name>, <string-name>
<given-names>N. J.</given-names>
<surname>Roberts</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Childs</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene</article-title>.&#x0201d; <source>JAMA Oncology</source>
<volume>7</volume>: <fpage>1664</fpage>&#x02013;<lpage>1668</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2021.3701</pub-id>.<pub-id pub-id-type="pmid">34529012</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0059"><mixed-citation publication-type="journal" id="pcmr13210-cit-0059">
<string-name>
<surname>Hu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hu</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Gu</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>micorRNA&#x02010;101 Silences DNA&#x02010;PKcs and Sensitizes Pancreatic Cancer Cells to Gemcitabine</article-title>.&#x0201d; <source>Biochemical and Biophysical Research Communications</source>
<volume>483</volume>: <fpage>725</fpage>&#x02013;<lpage>731</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.12.074</pub-id>.<pub-id pub-id-type="pmid">27988337</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0060"><mixed-citation publication-type="journal" id="pcmr13210-cit-0060">
<string-name>
<surname>Hu</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Qin</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ji</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>MTAP Deficiency&#x02010;Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>81</volume>: <fpage>4964</fpage>&#x02013;<lpage>4980</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0414</pub-id>.<pub-id pub-id-type="pmid">34385182</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0061"><mixed-citation publication-type="journal" id="pcmr13210-cit-0061">
<string-name>
<surname>Huang</surname>, <given-names>F. W.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Hodis</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>G. V.</given-names>
<surname>Kryukov</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Chin</surname>
</string-name>, and <string-name>
<given-names>L. A.</given-names>
<surname>Garraway</surname>
</string-name>. <year>2013</year>. &#x0201c;<article-title>Highly Recurrent TERT Promoter Mutations in Human Melanoma</article-title>.&#x0201d; <source>Science</source>
<volume>339</volume>: <fpage>957</fpage>&#x02013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1126/science.1229259</pub-id>.<pub-id pub-id-type="pmid">23348506</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0062"><mixed-citation publication-type="journal" id="pcmr13210-cit-0062">
<string-name>
<surname>Huang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Yuan</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhao</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>Gene Signature Developed for Predicting Early Relapse and Survival in Early&#x02010;Stage Pancreatic Cancer</article-title>.&#x0201d; <source>BJS Open</source>
<volume>7</volume>: zrad031. <pub-id pub-id-type="doi">10.1093/bjsopen/zrad031</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0063"><mixed-citation publication-type="journal" id="pcmr13210-cit-0063">
<string-name>
<surname>Johansson</surname>, <given-names>P. A.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Nathan</surname>
</string-name>, <string-name>
<given-names>L. M.</given-names>
<surname>Bourke</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Evaluation of the Contribution of Germline Variants in BRCA1 and BRCA2 to Uveal and Cutaneous Melanoma</article-title>.&#x0201d; <source>Melanoma Research</source>
<volume>29</volume>: <fpage>483</fpage>&#x02013;<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1097/CMR.0000000000000613</pub-id>.<pub-id pub-id-type="pmid">31464824</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0064"><mixed-citation publication-type="journal" id="pcmr13210-cit-0064">
<string-name>
<surname>Johnson</surname>, <given-names>D. B.</given-names>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Puzanov</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>Treatment of NRAS&#x02010;Mutant Melanoma</article-title>.&#x0201d; <source>Current Treatment Options in Oncology</source>
<volume>16</volume>: <fpage>15</fpage>. <pub-id pub-id-type="doi">10.1007/s11864-015-0330-z</pub-id>.<pub-id pub-id-type="pmid">25796376</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0065"><mixed-citation publication-type="journal" id="pcmr13210-cit-0065">
<string-name>
<surname>Kadokura</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Frydenlund</surname>
</string-name>, <string-name>
<given-names>D. A.</given-names>
<surname>Leone</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Neurofibromin Protein Loss in Desmoplastic Melanoma Subtypes: Implicating NF1 Allelic Loss as a Distinct Genetic Driver?</article-title>&#x0201d; <source>Human Pathology</source>
<volume>53</volume>: <fpage>82</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2016.02.012</pub-id>.<pub-id pub-id-type="pmid">26980030</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0066"><mixed-citation publication-type="journal" id="pcmr13210-cit-0066">
<string-name>
<surname>Karami Fath</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Azargoonjahromi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Soofi</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Current Understanding of Epigenetics Role in Melanoma Treatment and Resistance</article-title>.&#x0201d; <source>Cancer Cell International</source>
<volume>22</volume>: <fpage>313</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-022-02738-0</pub-id>.<pub-id pub-id-type="pmid">36224606</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0067"><mixed-citation publication-type="journal" id="pcmr13210-cit-0067">
<string-name>
<surname>Kastrinos</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Mukherjee</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Tayob</surname>
</string-name>, et&#x000a0;al. <year>2009</year>. &#x0201c;<article-title>Risk of Pancreatic Cancer in Families With Lynch Syndrome</article-title>.&#x0201d; <source>JAMA</source>
<volume>302</volume>: <fpage>1790</fpage>&#x02013;<lpage>1795</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2009.1529</pub-id>.<pub-id pub-id-type="pmid">19861671</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0068"><mixed-citation publication-type="journal" id="pcmr13210-cit-0068">
<string-name>
<surname>Kasuga</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Okamoto</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Udagawa</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume>: 1205. <pub-id pub-id-type="doi">10.3390/ijms23031205</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0069"><mixed-citation publication-type="journal" id="pcmr13210-cit-0069">
<string-name>
<surname>Kayed</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bekasi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Keleg</surname>
</string-name>, et&#x000a0;al. <year>2008</year>. &#x0201c;<article-title>Expression of the Shwachman&#x02010;Bodian&#x02010;Diamond Syndrome (SBDS) Protein in Human Pancreatic Cancer and Chronic Pancreatitis</article-title>.&#x0201d; <source>Histology and Histopathology</source>
<volume>23</volume>: <fpage>819</fpage>&#x02013;<lpage>826</lpage>. <pub-id pub-id-type="doi">10.14670/HH-23.819</pub-id>.<pub-id pub-id-type="pmid">18437680</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0070"><mixed-citation publication-type="journal" id="pcmr13210-cit-0070">
<string-name>
<surname>Khan</surname>, <given-names>S. U.</given-names>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Ullah</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Shaukat</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>TP53 and Its Regulatory Genes as Prognosis of Cutaneous Melanoma</article-title>.&#x0201d; <source>Cancer Informatics</source>
<volume>22</volume>. <pub-id pub-id-type="doi">10.1177/11769351231177267</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0071"><mixed-citation publication-type="journal" id="pcmr13210-cit-0071">
<string-name>
<surname>Klatte</surname>, <given-names>D. C. F.</given-names>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Wallace</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lohr</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Bruno</surname>
</string-name>, and <string-name>
<given-names>M. E.</given-names>
<surname>van Leerdam</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>Hereditary Pancreatic Cancer</article-title>.&#x0201d; <source>Best Practice &#x00026; Research. Clinical Gastroenterology</source>
<volume>58&#x02010;59</volume>: <elocation-id>101783</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.bpg.2021.101783</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0072"><mixed-citation publication-type="journal" id="pcmr13210-cit-0072">
<string-name>
<surname>Knudsen</surname>, <given-names>E. S.</given-names>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>O'Reilly</surname>
</string-name>, <string-name>
<given-names>J. R.</given-names>
<surname>Brody</surname>
</string-name>, and <string-name>
<given-names>A. K.</given-names>
<surname>Witkiewicz</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine</article-title>.&#x0201d; <source>Gastroenterology</source>
<volume>150</volume>: <fpage>48</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2015.08.056</pub-id>.<pub-id pub-id-type="pmid">26385075</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0073"><mixed-citation publication-type="journal" id="pcmr13210-cit-0073">
<string-name>
<surname>Kou</surname>, <given-names>Y. Q.</given-names>
</string-name>, <string-name>
<given-names>Y. P.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>Z. J.</given-names>
<surname>Pan</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>Prognostic&#x02010;Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating With Immune Infiltrates Based on Proteomics</article-title>.&#x0201d; <source>Medical Science Monitor</source>
<volume>29</volume>: <elocation-id>e938785</elocation-id>. <pub-id pub-id-type="doi">10.12659/MSM.938785</pub-id>.<pub-id pub-id-type="pmid">36905103</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0074"><mixed-citation publication-type="journal" id="pcmr13210-cit-0074">
<string-name>
<surname>Koutsioumpa</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hatziapostolou</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Polytarchou</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Lysine Methyltransferase 2D Regulates Pancreatic Carcinogenesis Through Metabolic Reprogramming</article-title>.&#x0201d; <source>Gut</source>
<volume>68</volume>: <fpage>1271</fpage>&#x02013;<lpage>1286</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2017-315690</pub-id>.<pub-id pub-id-type="pmid">30337373</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0075"><mixed-citation publication-type="journal" id="pcmr13210-cit-0075">
<string-name>
<surname>Kwon</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Lee</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Lee</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>BAP1 as a Guardian of Genome Stability: Implications in Human cancer</article-title>.&#x0201d; <source>Experimental &#x00026; Molecular Medicine</source>
<volume>55</volume>: <fpage>745</fpage>&#x02013;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-023-00979-1</pub-id>.<pub-id pub-id-type="pmid">37009801</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0076"><mixed-citation publication-type="journal" id="pcmr13210-cit-0076">
<string-name>
<surname>Lambertini</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mussi</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Nodular Melanoma in an MITF p.E318K Carrier Patient: The Wolf in Little Red Riding Hood</article-title>.&#x0201d; <source>Australasian Journal of Dermatology</source>
<volume>62</volume>: <fpage>e146</fpage>&#x02013;<lpage>e148</lpage>. <pub-id pub-id-type="doi">10.1111/ajd.13448</pub-id>.<pub-id pub-id-type="pmid">32895944</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0077"><mixed-citation publication-type="journal" id="pcmr13210-cit-0077">
<string-name>
<surname>Lambertini</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Zengarini</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Ravaioli</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>Multiple Primary Melanomas: Is There a Correlation Between Dermoscopic Features and Germline Mutations?</article-title>&#x0201d; <source>Australasian Journal of Dermatology</source>
<volume>64</volume>: <fpage>e182</fpage>&#x02013;<lpage>e185</lpage>. <pub-id pub-id-type="doi">10.1111/ajd.14007</pub-id>.<pub-id pub-id-type="pmid">36774630</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0078"><mixed-citation publication-type="journal" id="pcmr13210-cit-0078">
<string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Ye</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Comprehensive Genomic Analysis of Primary Malignant Melanoma of the Esophagus Reveals Similar Genetic Patterns Compared With Epithelium&#x02010;Associated Melanomas</article-title>.&#x0201d; <source>Modern Pathology</source>
<volume>35</volume>: <fpage>1596</fpage>&#x02013;<lpage>1608</lpage>. <pub-id pub-id-type="doi">10.1038/s41379-022-01116-5</pub-id>.<pub-id pub-id-type="pmid">35688970</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0079"><mixed-citation publication-type="journal" id="pcmr13210-cit-0079">
<string-name>
<surname>Li</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Guan</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ma</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Yang</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>MicroRNA&#x02010;488&#x02010;3p Sensitizes Malignant Melanoma Cells to Cisplatin by Targeting PRKDC</article-title>.&#x0201d; <source>Cell Biology International</source>
<volume>41</volume>: <fpage>622</fpage>&#x02013;<lpage>629</lpage>. <pub-id pub-id-type="doi">10.1002/cbin.10765</pub-id>.<pub-id pub-id-type="pmid">28328082</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0080"><mixed-citation publication-type="journal" id="pcmr13210-cit-0080">
<string-name>
<surname>Li</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Dai</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Yang</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Pan&#x02010;cancer Analysis of the PDE4DIP Gene With Potential Prognostic and Immunotherapeutic Values in Multiple Cancers Including Acute Myeloid Leukemia</article-title>.&#x0201d; <source>Open Medicine (Warsaw, Poland)</source>
<volume>18</volume>: <elocation-id>20230782</elocation-id>. <pub-id pub-id-type="doi">10.1515/med-2023-0782</pub-id>.<pub-id pub-id-type="pmid">37663233</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0081"><mixed-citation publication-type="journal" id="pcmr13210-cit-0081">
<string-name>
<surname>Liang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Meng</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>TGFB1&#x02010;Induced Autophagy Affects the Pattern of Pancreatic Cancer Progression in Distinct Ways Depending on SMAD4 Status</article-title>.&#x0201d; <source>Autophagy</source>
<volume>16</volume>: <fpage>486</fpage>&#x02013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2019.1628540</pub-id>.<pub-id pub-id-type="pmid">31177911</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0082"><mixed-citation publication-type="journal" id="pcmr13210-cit-0082">
<string-name>
<surname>Ling</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ishiai</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Ali</surname>
</string-name>, et&#x000a0;al. <year>2007</year>. &#x0201c;<article-title>FAAP100 Is Essential for Activation of the Fanconi anemia&#x02010;Associated DNA Damage Response Pathway</article-title>.&#x0201d; <source>EMBO Journal</source>
<volume>26</volume>: <fpage>2104</fpage>&#x02013;<lpage>2114</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7601666</pub-id>.<pub-id pub-id-type="pmid">17396147</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0083"><mixed-citation publication-type="journal" id="pcmr13210-cit-0083">
<string-name>
<surname>Lin&#x02010;Shiao</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Lan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Coradin</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>KMT2D Regulates p63 Target Enhancers to Coordinate Epithelial Homeostasis</article-title>.&#x0201d; <source>Genes &#x00026; Development</source>
<volume>32</volume>: <fpage>181</fpage>&#x02013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1101/gad.306241.117</pub-id>.<pub-id pub-id-type="pmid">29440247</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0084"><mixed-citation publication-type="journal" id="pcmr13210-cit-0084">
<string-name>
<surname>Lissanu Deribe</surname>, <given-names>Y.</given-names>
</string-name>
<year>2016</year>. &#x0201c;<article-title>Mechanistic Insights Into the Role of Truncating PREX2 Mutations in Melanoma</article-title>.&#x0201d; <source>Molecular &#x00026; Cellular Oncology</source>
<volume>3</volume>: <elocation-id>e1160174</elocation-id>. <pub-id pub-id-type="doi">10.1080/23723556.2016.1160174</pub-id>.<pub-id pub-id-type="pmid">27314100</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0085"><mixed-citation publication-type="journal" id="pcmr13210-cit-0085">
<string-name>
<surname>Liu</surname>, <given-names>Z. J.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Xiao</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Balint</surname>
</string-name>, et&#x000a0;al. <year>2006</year>. &#x0201c;<article-title>Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen&#x02010;Activated Protein Kinase/Phosphatidylinositol 3&#x02010;Kinase&#x02010;Akt Pathways and Up&#x02010;Regulating N&#x02010;Cadherin Expression</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>66</volume>: <fpage>4182</fpage>&#x02013;<lpage>4190</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3589</pub-id>.<pub-id pub-id-type="pmid">16618740</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0086"><mixed-citation publication-type="journal" id="pcmr13210-cit-0086">
<string-name>
<surname>Luo</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Tian</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Feng</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Yi</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>Q.</given-names>
<surname>Huang</surname>
</string-name>. <year>2013</year>. &#x0201c;<article-title>The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma</article-title>.&#x0201d; <source>Pathology Oncology Research</source>
<volume>19</volume>: <fpage>35</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/s12253-012-9555-3</pub-id>.<pub-id pub-id-type="pmid">22782330</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0087"><mixed-citation publication-type="journal" id="pcmr13210-cit-0087">
<string-name>
<surname>Lynch</surname>, <given-names>H. T.</given-names>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Fusaro</surname>
</string-name>, <string-name>
<given-names>J. F.</given-names>
<surname>Lynch</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Brand</surname>
</string-name>. <year>2008</year>. &#x0201c;<article-title>Pancreatic Cancer and the FAMMM Syndrome</article-title>.&#x0201d; <source>Familial Cancer</source>
<volume>7</volume>: <fpage>103</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-007-9166-4</pub-id>.<pub-id pub-id-type="pmid">17992582</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0088"><mixed-citation publication-type="journal" id="pcmr13210-cit-0088">
<string-name>
<surname>Lynch</surname>, <given-names>H. T.</given-names>
</string-name>, and <string-name>
<given-names>A. J.</given-names>
<surname>Krush</surname>
</string-name>. <year>1968</year>. &#x0201c;<article-title>Heredity and Malignant Melanoma: Implications for Early cancer Detection</article-title>.&#x0201d; <source>Canadian Medical Association Journal</source>
<volume>99</volume>: <fpage>17</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">5663000</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0089"><mixed-citation publication-type="journal" id="pcmr13210-cit-0089">
<string-name>
<surname>Manzano</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Layos</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Buges</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Resistant Mechanisms to BRAF Inhibitors in Melanoma</article-title>.&#x0201d; <source>Annals of Translational Medicine</source>
<volume>4</volume>: <fpage>237</fpage>. <pub-id pub-id-type="doi">10.21037/atm.2016.06.07</pub-id>.<pub-id pub-id-type="pmid">27429963</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0090"><mixed-citation publication-type="journal" id="pcmr13210-cit-0090">
<string-name>
<surname>Mar</surname>, <given-names>V. J.</given-names>
</string-name>, <string-name>
<given-names>S. Q.</given-names>
<surname>Wong</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Logan</surname>
</string-name>, et&#x000a0;al. <year>2014</year>. &#x0201c;<article-title>Clinical and Pathological Associations of the Activating RAC1 P29S Mutation in Primary Cutaneous Melanoma</article-title>.&#x0201d; <source>Pigment Cell &#x00026; Melanoma Research</source>
<volume>27</volume>: <fpage>1117</fpage>&#x02013;<lpage>1125</lpage>. <pub-id pub-id-type="doi">10.1111/pcmr.12295</pub-id>.<pub-id pub-id-type="pmid">25043693</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0091"><mixed-citation publication-type="journal" id="pcmr13210-cit-0091">
<string-name>
<surname>McNeal</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Nakhate</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>CDKN2B Loss Promotes Progression From Benign Melanocytic Nevus to Melanoma</article-title>.&#x0201d; <source>Cancer Discovery</source>
<volume>5</volume>: <fpage>1072</fpage>&#x02013;<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0196</pub-id>.<pub-id pub-id-type="pmid">26183406</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0092"><mixed-citation publication-type="journal" id="pcmr13210-cit-0092">
<string-name>
<surname>Mirjacic Martinovic</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Vuletic</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Malisic</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Increased Circulating TGF&#x02010;beta1 Is Associated With Impairment in NK Cell Effector Functions in Metastatic Melanoma Patients</article-title>.&#x0201d; <source>Growth Factors</source>
<volume>40</volume>: <fpage>231</fpage>&#x02013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1080/08977194.2022.2124915</pub-id>.<pub-id pub-id-type="pmid">36129407</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0093"><mixed-citation publication-type="journal" id="pcmr13210-cit-0093">
<string-name>
<surname>Morani</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<given-names>A. K.</given-names>
<surname>Hanafy</surname>
</string-name>, <string-name>
<given-names>N. S.</given-names>
<surname>Ramani</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging</article-title>.&#x0201d; <source>Radiology: Imaging Cancer</source>
<volume>2</volume>: <elocation-id>e190020</elocation-id>. <pub-id pub-id-type="doi">10.1148/rycan.2020190020</pub-id>.<pub-id pub-id-type="pmid">33778702</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0094"><mixed-citation publication-type="journal" id="pcmr13210-cit-0094">
<string-name>
<surname>Moscarella</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Pellegrini</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pampena</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Dermoscopic Similarity Is an Independent Predictor of BRAF Mutational Concordance in Multiple Melanomas</article-title>.&#x0201d; <source>Experimental Dermatology</source>
<volume>28</volume>: <fpage>829</fpage>&#x02013;<lpage>835</lpage>. <pub-id pub-id-type="doi">10.1111/exd.13951</pub-id>.<pub-id pub-id-type="pmid">31034104</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0095"><mixed-citation publication-type="journal" id="pcmr13210-cit-0095">
<string-name>
<surname>Murtas</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Piras</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Minerba</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Activated Notch1 Expression Is Associated With Angiogenesis in Cutaneous Melanoma</article-title>.&#x0201d; <source>Clinical and Experimental Medicine</source>
<volume>15</volume>: <fpage>351</fpage>&#x02013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1007/s10238-014-0300-y</pub-id>.<pub-id pub-id-type="pmid">25034654</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0096"><mixed-citation publication-type="journal" id="pcmr13210-cit-0096">
<string-name>
<surname>Murugesan</surname>, <given-names>N.</given-names>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Maitituoheti</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>KMT2D Deficiency Confers a Therapeutic Vulnerability to Glycolytic and IGFR Inhibitors in Melanoma</article-title>.&#x0201d; <source>Molecular &#x00026; Cellular Oncology</source>
<volume>8</volume>: <elocation-id>1984827</elocation-id>. <pub-id pub-id-type="doi">10.1080/23723556.2021.1984827</pub-id>.<pub-id pub-id-type="pmid">34859145</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0097"><mixed-citation publication-type="journal" id="pcmr13210-cit-0097">
<string-name>
<surname>Naddeo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Broseghini</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Venturi</surname>
</string-name>, et&#x000a0;al. <year>2024</year>. &#x0201c;<article-title>Association of miR&#x02010;146a&#x02010;5p and miR&#x02010;21&#x02010;5p With Prognostic Features in Melanomas</article-title>.&#x0201d; <source>Cancers (Basel)</source>
<volume>16</volume>: 1688. <pub-id pub-id-type="doi">10.3390/cancers16091688</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0098"><mixed-citation publication-type="book" id="pcmr13210-cit-0098">
<string-name>
<surname>Nelson</surname>, <given-names>H. D.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Fu</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Goddard</surname>
</string-name>, et&#x000a0;al. <year>2013</year>. <source>Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA&#x02010;Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation</source>. Vol. <volume>160</volume>, <fpage>255</fpage>&#x02013;<lpage>266</lpage>. <publisher-loc>Rockville (MD)</publisher-loc>: <publisher-name>U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews</publisher-name>.</mixed-citation></ref><ref id="pcmr13210-bib-0099"><mixed-citation publication-type="journal" id="pcmr13210-cit-0099">
<string-name>
<surname>Nikolaev</surname>, <given-names>S. I.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Rimoldi</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Iseli</surname>
</string-name>, et&#x000a0;al. <year>2011</year>. &#x0201c;<article-title>Exome Sequencing Identifies Recurrent Somatic MAP2K1 and MAP2K2 Mutations in Melanoma</article-title>.&#x0201d; <source>Nature Genetics</source>
<volume>44</volume>: <fpage>133</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1038/ng.1026</pub-id>.<pub-id pub-id-type="pmid">22197931</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0100"><mixed-citation publication-type="journal" id="pcmr13210-cit-0100">
<string-name>
<surname>Oketch</surname>, <given-names>D. J. A.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Giulietti</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Piva</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>25</volume>: 391. <pub-id pub-id-type="doi">10.3390/ijms25010391</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0101"><mixed-citation publication-type="journal" id="pcmr13210-cit-0101">
<string-name>
<surname>Patra</surname>, <given-names>K. C.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Kato</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mizukami</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Mutant GNAS Drives Pancreatic Tumourigenesis by Inducing PKA&#x02010;Mediated SIK Suppression and Reprogramming Lipid Metabolism</article-title>.&#x0201d; <source>Nature Cell Biology</source>
<volume>20</volume>: <fpage>811</fpage>&#x02013;<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1038/s41556-018-0122-3</pub-id>.<pub-id pub-id-type="pmid">29941929</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0102"><mixed-citation publication-type="journal" id="pcmr13210-cit-0102">
<string-name>
<surname>Pauley</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Khan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Kohlmann</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Jeter</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants</article-title>.&#x0201d; <source>Frontiers in Oncology</source>
<volume>12</volume>: <elocation-id>837057</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2022.837057</pub-id>.<pub-id pub-id-type="pmid">35372037</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0103"><mixed-citation publication-type="journal" id="pcmr13210-cit-0103">
<string-name>
<surname>Pompella</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Tirino</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Pappalardo</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>21</volume>: 2814. <pub-id pub-id-type="doi">10.3390/ijms21082814</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0104"><mixed-citation publication-type="journal" id="pcmr13210-cit-0104">
<string-name>
<surname>Potrony</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Badenas</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Aguilera</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Update in Genetic Susceptibility in Melanoma</article-title>.&#x0201d; <source>Annals of Translational Medicine</source>
<volume>3</volume>: <fpage>210</fpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2305-5839.2015.08.11</pub-id>.<pub-id pub-id-type="pmid">26488006</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0105"><mixed-citation publication-type="journal" id="pcmr13210-cit-0105">
<string-name>
<surname>Principe</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>I. J.</given-names>
<surname>Dionisio de Sousa</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Prazeres</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Soares</surname>
</string-name>, and <string-name>
<given-names>R. T.</given-names>
<surname>Lima</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>LRP1B: A Giant Lost in Cancer Translation</article-title>.&#x0201d; <source>Pharmaceuticals (Basel)</source>
<volume>14: 836</volume>. <pub-id pub-id-type="doi">10.3390/ph14090836</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0106"><mixed-citation publication-type="journal" id="pcmr13210-cit-0106">
<string-name>
<surname>Puntervoll</surname>, <given-names>H. E.</given-names>
</string-name>, <string-name>
<given-names>X. R.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>H. H.</given-names>
<surname>Vetti</surname>
</string-name>, et&#x000a0;al. <year>2013</year>. &#x0201c;<article-title>Melanoma Prone Families With CDK4 Germline Mutation: Phenotypic Profile and Associations With MC1R Variants</article-title>.&#x0201d; <source>Journal of Medical Genetics</source>
<volume>50</volume>: <fpage>264</fpage>&#x02013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2012-101455</pub-id>.<pub-id pub-id-type="pmid">23384855</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0107"><mixed-citation publication-type="journal" id="pcmr13210-cit-0107">
<string-name>
<surname>Querzoli</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Veronesi</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Corti</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Nottegar</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Basic Elements of Artificial Intelligence Tools in the Diagnosis of Cutaneous Melanoma</article-title>.&#x0201d; <source>Critical Reviews in Oncogenesis</source>
<volume>28</volume>: <fpage>37</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1615/CritRevOncog.2023050220</pub-id>.<pub-id pub-id-type="pmid">37968992</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0108"><mixed-citation publication-type="journal" id="pcmr13210-cit-0108">
<string-name>
<surname>Ravaioli</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lambertini</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Chessa</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Fanti</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Patrizi</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Acral Melanoma: Correlating the Clinical Presentation to the Mutational Status</article-title>.&#x0201d; <source>Giornale Italiano di Dermatologia e Venereologia</source>
<volume>154</volume>: <fpage>567</fpage>&#x02013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.23736/S0392-0488.18.05791-7</pub-id>.<pub-id pub-id-type="pmid">29512974</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0109"><mixed-citation publication-type="journal" id="pcmr13210-cit-0109">
<string-name>
<surname>Ribeiro Moura Brasil Arnaut</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Dos Santos Guimar&#x000e3;es</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Evangelista Dos Santos</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>de Moraes Lino da Silva</surname>
</string-name>, <string-name>
<given-names>J. R.</given-names>
<surname>Machado</surname>
</string-name>, and <string-name>
<given-names>A. C.</given-names>
<surname>de Melo</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Molecular Landscape of Hereditary Melanoma</article-title>.&#x0201d; <source>Critical Reviews in Oncology/Hematology</source>
<volume>164</volume>: <elocation-id>103425</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2021.103425</pub-id>.<pub-id pub-id-type="pmid">34245855</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0110"><mixed-citation publication-type="journal" id="pcmr13210-cit-0110">
<string-name>
<surname>Ribero</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lambertini</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ferracin</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Non&#x02010;Coding RNA Investigations in Cutaneous Melanoma: A Step Forward in Discovering Novel Biomarkers</article-title>.&#x0201d; <source>Journal of Investigative Dermatology</source>
<volume>143</volume>: <fpage>531</fpage>&#x02013;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2023.02.005</pub-id>.<pub-id pub-id-type="pmid">36841674</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0111"><mixed-citation publication-type="journal" id="pcmr13210-cit-0111">
<string-name>
<surname>Ribero</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Longo</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Glass</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Nathan</surname>
</string-name>, and <string-name>
<given-names>V.</given-names>
<surname>Bataille</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>What Is New in Melanoma Genetics and Treatment?</article-title>&#x0201d; <source>Dermatology</source>
<volume>232</volume>: <fpage>259</fpage>&#x02013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1159/000445767</pub-id>.<pub-id pub-id-type="pmid">27173969</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0112"><mixed-citation publication-type="journal" id="pcmr13210-cit-0112">
<string-name>
<surname>Ricci</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Ambrosi</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Grillini</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Next&#x02010;Generation Sequencing Revealing TP53 Mutation as Potential Genetic Driver in Dermal Deep&#x02010;Seated Melanoma Arising in Giant Congenital Nevus in Adult Patients: A Unique Case Report and Review of the Literature</article-title>.&#x0201d; <source>Journal of Cutaneous Pathology</source>
<volume>47</volume>: <fpage>1164</fpage>&#x02013;<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.1111/cup.13802</pub-id>.<pub-id pub-id-type="pmid">32643812</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0113"><mixed-citation publication-type="journal" id="pcmr13210-cit-0113">
<string-name>
<surname>Ricci</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Ambrosi</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lambertini</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Veronesi</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Barbara</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume>: 5911. <pub-id pub-id-type="doi">10.3390/ijms23115911</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0114"><mixed-citation publication-type="journal" id="pcmr13210-cit-0114">
<string-name>
<surname>Richards</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Aziz</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bale</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>.&#x0201d; <source>Genetics in Medicine</source>
<volume>17</volume>: <fpage>405</fpage>&#x02013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>.<pub-id pub-id-type="pmid">25741868</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0115"><mixed-citation publication-type="journal" id="pcmr13210-cit-0115">
<string-name>
<surname>Riefolo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Porcellini</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Broseghini</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ferracin</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Interplay Between Small and Long Non&#x02010;coding RNAs in Cutaneous Melanoma: A Complex Jigsaw Puzzle With Missing Pieces</article-title>.&#x0201d; <source>Molecular Oncology</source>
<volume>13</volume>: <fpage>74</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.12412</pub-id>.<pub-id pub-id-type="pmid">30499222</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0116"><mixed-citation publication-type="journal" id="pcmr13210-cit-0116">
<string-name>
<surname>Robles&#x02010;Espinoza</surname>, <given-names>C. D.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Harland</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Ramsay</surname>
</string-name>, et&#x000a0;al. <year>2014</year>. &#x0201c;<article-title>POT1 Loss&#x02010;Of&#x02010;Function Variants Predispose to Familial Melanoma</article-title>.&#x0201d; <source>Nature Genetics</source>
<volume>46</volume>: <fpage>478</fpage>&#x02013;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2947</pub-id>.<pub-id pub-id-type="pmid">24686849</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0117"><mixed-citation publication-type="journal" id="pcmr13210-cit-0117">
<string-name>
<surname>Rogers</surname>, <given-names>C. D.</given-names>
</string-name>, <string-name>
<given-names>F. J.</given-names>
<surname>Couch</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Brune</surname>
</string-name>, et&#x000a0;al. <year>2004</year>. &#x0201c;<article-title>Genetics of the FANCA Gene in Familial Pancreatic Cancer</article-title>.&#x0201d; <source>Journal of Medical Genetics</source>
<volume>41</volume>: <elocation-id>e126</elocation-id>. <pub-id pub-id-type="doi">10.1136/jmg.2004.024851</pub-id>.<pub-id pub-id-type="pmid">15591268</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0118"><mixed-citation publication-type="journal" id="pcmr13210-cit-0118">
<string-name>
<surname>Rossi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Pellegrini</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Cardelli</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Ciciarelli</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Di Nardo</surname>
</string-name>, and <string-name>
<given-names>M. C.</given-names>
<surname>Fargnoli</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Familial Melanoma: Diagnostic and Management Implications</article-title>.&#x0201d; <source>Dermatology Practical &#x00026; Conceptual</source>
<volume>9</volume>: <fpage>10</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.5826/dpc.0901a03</pub-id>.<pub-id pub-id-type="pmid">30775140</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0119"><mixed-citation publication-type="journal" id="pcmr13210-cit-0119">
<string-name>
<surname>Rowan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Bataille</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>MacKie</surname>
</string-name>, et&#x000a0;al. <year>1999</year>. &#x0201c;<article-title>Somatic Mutations in the Peutz&#x02010;Jeghers (LKB1/STKII) Gene in Sporadic Malignant Melanomas</article-title>.&#x0201d; <source>Journal of Investigative Dermatology</source>
<volume>112</volume>: <fpage>509</fpage>&#x02013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.1999.00551.x</pub-id>.<pub-id pub-id-type="pmid">10201537</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0120"><mixed-citation publication-type="journal" id="pcmr13210-cit-0120">
<string-name>
<surname>Ruijs</surname>, <given-names>M. W.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Verhoef</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Rookus</surname>
</string-name>, et&#x000a0;al. <year>2010</year>. &#x0201c;<article-title>TP53 Germline Mutation Testing in 180 Families Suspected of Li&#x02010;Fraumeni Syndrome: Mutation Detection Rate and Relative Frequency of Cancers in Different Familial Phenotypes</article-title>.&#x0201d; <source>Journal of Medical Genetics</source>
<volume>47</volume>: <fpage>421</fpage>&#x02013;<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2009.073429</pub-id>.<pub-id pub-id-type="pmid">20522432</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0121"><mixed-citation publication-type="journal" id="pcmr13210-cit-0121">
<string-name>
<surname>Saloustros</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Salpea</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Starost</surname>
</string-name>, et&#x000a0;al. <year>2017</year>. &#x0201c;<article-title>Prkar1a Gene Knockout in the Pancreas Leads to Neuroendocrine Tumorigenesis</article-title>.&#x0201d; <source>Endocrine&#x02010;Related Cancer</source>
<volume>24</volume>: <fpage>31</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1530/ERC-16-0443</pub-id>.<pub-id pub-id-type="pmid">27803029</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0122"><mixed-citation publication-type="journal" id="pcmr13210-cit-0122">
<string-name>
<surname>Sausen</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Phallen</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Adleff</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Clinical Implications of Genomic Alterations in the Tumour and Circulation of Pancreatic Cancer Patients</article-title>.&#x0201d; <source>Nature Communications</source>
<volume>6</volume>: <fpage>7686</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8686</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0123"><mixed-citation publication-type="journal" id="pcmr13210-cit-0123">
<string-name>
<surname>Sauter</surname>, <given-names>E. R.</given-names>
</string-name>, <string-name>
<given-names>U. C.</given-names>
<surname>Yeo</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>von Stemm</surname>
</string-name>, et&#x000a0;al. <year>2002</year>. &#x0201c;<article-title>Cyclin D1 Is a Candidate Oncogene in Cutaneous Melanoma</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>62</volume>: <fpage>3200</fpage>&#x02013;<lpage>3206</lpage>.<pub-id pub-id-type="pmid">12036934</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0124"><mixed-citation publication-type="journal" id="pcmr13210-cit-0124">
<string-name>
<surname>Scarfi</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Patrizi</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Veronesi</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>The Role of Topical Imiquimod in Melanoma Cutaneous Metastases: A Critical Review of the Literature</article-title>.&#x0201d; <source>Dermatologic Therapy</source>
<volume>33</volume>: <elocation-id>e14165</elocation-id>. <pub-id pub-id-type="doi">10.1111/dth.14165</pub-id>.<pub-id pub-id-type="pmid">32772481</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0125"><mixed-citation publication-type="journal" id="pcmr13210-cit-0125">
<string-name>
<surname>Secq</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Leca</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bressy</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Stromal SLIT2 Impacts on Pancreatic Cancer&#x02010;Associated Neural Remodeling</article-title>.&#x0201d; <source>Cell Death &#x00026; Disease</source>
<volume>6</volume>: <elocation-id>e1592</elocation-id>. <pub-id pub-id-type="doi">10.1038/cddis.2014.557</pub-id>.<pub-id pub-id-type="pmid">25590802</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0126"><mixed-citation publication-type="journal" id="pcmr13210-cit-0126">
<string-name>
<surname>Shain</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Yeh</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Kovalyshyn</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>The Genetic Evolution of Melanoma From Precursor Lesions</article-title>.&#x0201d; <source>New England Journal of Medicine</source>
<volume>373</volume>: <fpage>1926</fpage>&#x02013;<lpage>1936</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1502583</pub-id>.<pub-id pub-id-type="pmid">26559571</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0127"><mixed-citation publication-type="journal" id="pcmr13210-cit-0127">
<string-name>
<surname>Stadler</surname>, <given-names>Z. K.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Salo&#x02010;Mullen</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Patil</surname>
</string-name>, et&#x000a0;al. <year>2012</year>. &#x0201c;<article-title>Prevalence of BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Families With Breast and Pancreatic Cancer</article-title>.&#x0201d; <source>Cancer</source>
<volume>118</volume>: <fpage>493</fpage>&#x02013;<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.26191</pub-id>.<pub-id pub-id-type="pmid">21598239</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0128"><mixed-citation publication-type="journal" id="pcmr13210-cit-0128">
<string-name>
<surname>Starace</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dika</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Fanti</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Nail Apparatus Melanoma: Dermoscopic and Histopathologic Correlations on a Series of 23 Patients From a Single Centre</article-title>.&#x0201d; <source>Journal of the European Academy of Dermatology and Venereology</source>
<volume>32</volume>: <fpage>164</fpage>&#x02013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1111/jdv.14568</pub-id>.<pub-id pub-id-type="pmid">28850750</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0129"><mixed-citation publication-type="journal" id="pcmr13210-cit-0129">
<string-name>
<surname>Stoof</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Harrold</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Mariottino</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Lowery</surname>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>Walsh</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives</article-title>.&#x0201d; <source>Frontiers in Cell and Development Biology</source>
<volume>9</volume>: <elocation-id>749490</elocation-id>. <pub-id pub-id-type="doi">10.3389/fcell.2021.749490</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0130"><mixed-citation publication-type="journal" id="pcmr13210-cit-0130">
<string-name>
<surname>Taniuchi</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Nakagawa</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hosokawa</surname>
</string-name>, et&#x000a0;al. <year>2005</year>. &#x0201c;<article-title>Overexpressed P&#x02010;Cadherin/CDH3 Promotes Motility of Pancreatic Cancer Cells by Interacting With p120ctn and Activating Rho&#x02010;Family GTPases</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>65</volume>: <fpage>3092</fpage>&#x02013;<lpage>3099</lpage>. <pub-id pub-id-type="doi">10.1158/0008.5472.CAN-04-3646</pub-id>.<pub-id pub-id-type="pmid">15833838</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0131"><mixed-citation publication-type="journal" id="pcmr13210-cit-0131">
<string-name>
<surname>Thielmann</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Matull</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Roth</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load Without Implications on Patient Survival</article-title>.&#x0201d; <source>Cancers (Basel)</source>
<volume>14</volume>: 2090. <pub-id pub-id-type="doi">10.3390/cancers14092090</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0132"><mixed-citation publication-type="journal" id="pcmr13210-cit-0132">
<string-name>
<surname>Toussi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Mans</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Welborn</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Kiuru</surname>
</string-name>. <year>2020</year>. &#x0201c;<article-title>Germline Mutations Predisposing to Melanoma</article-title>.&#x0201d; <source>Journal of Cutaneous Pathology</source>
<volume>47</volume>: <fpage>606</fpage>&#x02013;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1111/cup.13689</pub-id>.<pub-id pub-id-type="pmid">32249949</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0133"><mixed-citation publication-type="journal" id="pcmr13210-cit-0133">
<string-name>
<surname>van Asperen</surname>, <given-names>C. J.</given-names>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Brohet</surname>
</string-name>, <string-name>
<given-names>E. J.</given-names>
<surname>Meijers&#x02010;Heijboer</surname>
</string-name>, et&#x000a0;al. <year>2005</year>. &#x0201c;<article-title>Cancer Risks in BRCA2 Families: Estimates for Sites Other Than Breast and Ovary</article-title>.&#x0201d; <source>Journal of Medical Genetics</source>
<volume>42</volume>: <fpage>711</fpage>&#x02013;<lpage>719</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2004.028829</pub-id>.<pub-id pub-id-type="pmid">16141007</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0134"><mixed-citation publication-type="journal" id="pcmr13210-cit-0134">
<string-name>
<surname>van Leerdam</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<given-names>V. H.</given-names>
<surname>Roos</surname>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>van Hooft</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Endoscopic Management of Lynch Syndrome and of Familial Risk of Colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline</article-title>.&#x0201d; <source>Endoscopy</source>
<volume>51</volume>: <fpage>1082</fpage>&#x02013;<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1055/a-1016-4977</pub-id>.<pub-id pub-id-type="pmid">31597170</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0135"><mixed-citation publication-type="journal" id="pcmr13210-cit-0135">
<string-name>
<surname>van Lier</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Wagner</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Mathus&#x02010;Vliegen</surname>
</string-name>, <string-name>
<given-names>E. J.</given-names>
<surname>Kuipers</surname>
</string-name>, <string-name>
<given-names>E. W.</given-names>
<surname>Steyerberg</surname>
</string-name>, and <string-name>
<given-names>M. E.</given-names>
<surname>van Leerdam</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>High cancer Risk in Peutz&#x02010;Jeghers Syndrome: A Systematic Review and Surveillance Recommendations</article-title>.&#x0201d; <source>American Journal of Gastroenterology</source>
<volume>105</volume>: <fpage>1258</fpage>&#x02013;<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1038/ajg.2009.725</pub-id>.<pub-id pub-id-type="pmid">20051941</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0136"><mixed-citation publication-type="journal" id="pcmr13210-cit-0136">
<string-name>
<surname>Vasen</surname>, <given-names>H. F.</given-names>
</string-name>, <string-name>
<given-names>N. A.</given-names>
<surname>Gruis</surname>
</string-name>, <string-name>
<given-names>R. R.</given-names>
<surname>Frants</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>van Der Velden</surname>
</string-name>, <string-name>
<given-names>E. T.</given-names>
<surname>Hille</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Bergman</surname>
</string-name>. <year>2000</year>. &#x0201c;<article-title>Risk of Developing Pancreatic Cancer in Families With Familial Atypical Multiple Mole Melanoma Associated With a Specific 19 Deletion of p16 (p16&#x02010;Leiden)</article-title>.&#x0201d; <source>International Journal of Cancer</source>
<volume>87</volume>: <fpage>809</fpage>&#x02013;<lpage>811</lpage>.<pub-id pub-id-type="pmid">10956390</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0137"><mixed-citation publication-type="journal" id="pcmr13210-cit-0137">
<string-name>
<surname>Vasen</surname>, <given-names>H. F.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Moslein</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Alonso</surname>
</string-name>, et&#x000a0;al. <year>2008</year>. &#x0201c;<article-title>Guidelines for the Clinical Management of Familial Adenomatous Polyposis (FAP)</article-title>.&#x0201d; <source>Gut</source>
<volume>57</volume>: <fpage>704</fpage>&#x02013;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1136/gut.2007.136127</pub-id>.<pub-id pub-id-type="pmid">18194984</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0138"><mixed-citation publication-type="journal" id="pcmr13210-cit-0138">
<string-name>
<surname>Vu</surname>, <given-names>H. L.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Rosenbaum</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Purwin</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Davies</surname>
</string-name>, and <string-name>
<given-names>A. E.</given-names>
<surname>Aplin</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>RAC1 P29S Regulates PD&#x02010;L1 Expression in Melanoma</article-title>.&#x0201d; <source>Pigment Cell &#x00026; Melanoma Research</source>
<volume>28</volume>: <fpage>590</fpage>&#x02013;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1111/pcmr.12392</pub-id>.<pub-id pub-id-type="pmid">26176707</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0139"><mixed-citation publication-type="journal" id="pcmr13210-cit-0139">
<string-name>
<surname>Waddell</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Pajic</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Patch</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Whole Genomes Redefine the Mutational Landscape of Pancreatic Cancer</article-title>.&#x0201d; <source>Nature</source>
<volume>518</volume>: <fpage>495</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1038/nature14169</pub-id>.<pub-id pub-id-type="pmid">25719666</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0140"><mixed-citation publication-type="journal" id="pcmr13210-cit-0140">
<string-name>
<surname>Watson</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>H. F. A.</given-names>
<surname>Vasen</surname>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>Mecklin</surname>
</string-name>, et&#x000a0;al. <year>2008</year>. &#x0201c;<article-title>The Risk of Extra&#x02010;Colonic, Extra&#x02010;Endometrial cancer in the Lynch Syndrome</article-title>.&#x0201d; <source>International Journal of Cancer</source>
<volume>123</volume>: <fpage>444</fpage>&#x02013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.23508</pub-id>.<pub-id pub-id-type="pmid">18398828</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0141"><mixed-citation publication-type="journal" id="pcmr13210-cit-0141">
<string-name>
<surname>Wellbrock</surname>, <given-names>C.</given-names>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Arozarena</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>Microphthalmia&#x02010;Associated Transcription Factor in Melanoma Development and MAP&#x02010;Kinase Pathway Targeted Therapy</article-title>.&#x0201d; <source>Pigment Cell &#x00026; Melanoma Research</source>
<volume>28</volume>: <fpage>390</fpage>&#x02013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1111/pcmr.12370</pub-id>.<pub-id pub-id-type="pmid">25818589</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0142"><mixed-citation publication-type="journal" id="pcmr13210-cit-0142">
<string-name>
<surname>Wild</surname>, <given-names>P. J.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Meyer</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Landthaler</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Hofstaedter</surname>
</string-name>, and <string-name>
<given-names>A. K.</given-names>
<surname>Bosserhoff</surname>
</string-name>. <year>2007</year>. &#x0201c;<article-title>A Potential Predictive Marker for Response to Interferon in Malignant Melanoma</article-title>.&#x0201d; <source>Journal der Deutschen Dermatologischen Gesellschaft</source>
<volume>5</volume>: <fpage>456</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1111/j.1610-0387.2007.06303.x</pub-id>.<pub-id pub-id-type="pmid">17537037</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0143"><mixed-citation publication-type="journal" id="pcmr13210-cit-0143">
<string-name>
<surname>Williams</surname>, <given-names>P. F.</given-names>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Olsen</surname>
</string-name>, <string-name>
<given-names>N. K.</given-names>
<surname>Hayward</surname>
</string-name>, and <string-name>
<given-names>D. C.</given-names>
<surname>Whiteman</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>Melanocortin 1 Receptor and Risk of Cutaneous Melanoma: A meta&#x02010;Analysis and Estimates of Population Burden</article-title>.&#x0201d; <source>International Journal of Cancer</source>
<volume>129</volume>: <fpage>1730</fpage>&#x02013;<lpage>1740</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25804</pub-id>.<pub-id pub-id-type="pmid">21128237</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0144"><mixed-citation publication-type="journal" id="pcmr13210-cit-0144">
<string-name>
<surname>Witkiewicz</surname>, <given-names>A. K.</given-names>
</string-name>, <string-name>
<given-names>E. A.</given-names>
<surname>McMillan</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Balaji</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Whole&#x02010;Exome Sequencing of Pancreatic Cancer Defines Genetic Diversity and Therapeutic Targets</article-title>.&#x0201d; <source>Nature Communications</source>
<volume>6</volume>: <fpage>6744</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7744</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0145"><mixed-citation publication-type="journal" id="pcmr13210-cit-0145">
<string-name>
<surname>Wolf Horrell</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Boulanger</surname>
</string-name>, and <string-name>
<given-names>J. A.</given-names>
<surname>D'Orazio</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Melanocortin 1 Receptor: Structure, Function, and Regulation</article-title>.&#x0201d; <source>Frontiers in Genetics</source>
<volume>7</volume>: <elocation-id>95</elocation-id>. <pub-id pub-id-type="doi">10.3389/fgene.2016.00095</pub-id>.<pub-id pub-id-type="pmid">27303435</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0146"><mixed-citation publication-type="journal" id="pcmr13210-cit-0146">
<string-name>
<surname>Wood</surname>, <given-names>L. D.</given-names>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Yurgelun</surname>
</string-name>, and <string-name>
<given-names>M. G.</given-names>
<surname>Goggins</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Genetics of Familial and Sporadic Pancreatic Cancer</article-title>.&#x0201d; <source>Gastroenterology</source>
<volume>156</volume>: <fpage>2041</fpage>&#x02013;<lpage>2055</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2018.12.039</pub-id>.<pub-id pub-id-type="pmid">30660730</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0147"><mixed-citation publication-type="journal" id="pcmr13210-cit-0147">
<string-name>
<surname>Wu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Tang</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma</article-title>.&#x0201d; <source>Journal of Oncology</source>
<volume>2022</volume>: <elocation-id>4148805</elocation-id>. <pub-id pub-id-type="doi">10.1155/2022/4148805</pub-id>.<pub-id pub-id-type="pmid">35378770</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0148"><mixed-citation publication-type="journal" id="pcmr13210-cit-0148">
<string-name>
<surname>Yamamoto</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Tateishi</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Kudo</surname>
</string-name>, et&#x000a0;al. <year>2014</year>. &#x0201c;<article-title>Loss of Histone Demethylase KDM6B Enhances Aggressiveness of Pancreatic Cancer Through Downregulation of C/EBPalpha</article-title>.&#x0201d; <source>Carcinogenesis</source>
<volume>35</volume>: <fpage>2404</fpage>&#x02013;<lpage>2414</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgu136</pub-id>.<pub-id pub-id-type="pmid">24947179</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0149"><mixed-citation publication-type="journal" id="pcmr13210-cit-0149">
<string-name>
<surname>Yin</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Genetic Variants in Fanconi anemia Pathway Genes BRCA2 and FANCA Predict Melanoma Survival</article-title>.&#x0201d; <source>Journal of Investigative Dermatology</source>
<volume>135</volume>: <fpage>542</fpage>&#x02013;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2014.416</pub-id>.<pub-id pub-id-type="pmid">25243787</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0150"><mixed-citation publication-type="journal" id="pcmr13210-cit-0150">
<string-name>
<surname>Yokoyama</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Woods</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Boyle</surname>
</string-name>, et&#x000a0;al. <year>2011</year>. &#x0201c;<article-title>A Novel Recurrent Mutation in MITF Predisposes to Familial and Sporadic Melanoma</article-title>.&#x0201d; <source>Nature</source>
<volume>480</volume>: <fpage>99</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1038/nature10630</pub-id>.<pub-id pub-id-type="pmid">22080950</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0151"><mixed-citation publication-type="journal" id="pcmr13210-cit-0151">
<string-name>
<surname>Zade</surname>, <given-names>N. H.</given-names>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Khattar</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>POT1 Mutations Cause Differential Effects on Telomere Length Leading to Opposing Disease Phenotypes</article-title>.&#x0201d; <source>Journal of Cellular Physiology</source>
<volume>238</volume>: <fpage>1237</fpage>&#x02013;<lpage>1255</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.31034</pub-id>.<pub-id pub-id-type="pmid">37183325</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0152"><mixed-citation publication-type="journal" id="pcmr13210-cit-0152">
<string-name>
<surname>Zhang</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<given-names>P. S.</given-names>
<surname>Rush</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Tsao</surname>
</string-name>, and <string-name>
<given-names>L. M.</given-names>
<surname>Duncan</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>BRCA1&#x02010;Associated Protein (BAP1)&#x02010;inactivated Melanocytic Tumors</article-title>.&#x0201d; <source>Journal of Cutaneous Pathology</source>
<volume>46</volume>: <fpage>965</fpage>&#x02013;<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1111/cup.13530</pub-id>.<pub-id pub-id-type="pmid">31233225</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0153"><mixed-citation publication-type="journal" id="pcmr13210-cit-0153">
<string-name>
<surname>Zhou</surname>, <given-names>J. X.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>Q. J.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Association Between High Levels of Notch3 Expression and High Invasion and Poor Overall Survival Rates in Pancreatic Ductal Adenocarcinoma</article-title>.&#x0201d; <source>Oncology Reports</source>
<volume>36</volume>: <fpage>2893</fpage>&#x02013;<lpage>2901</lpage>. <pub-id pub-id-type="doi">10.3892/or.2016.5079</pub-id>.<pub-id pub-id-type="pmid">27633819</pub-id>
</mixed-citation></ref><ref id="pcmr13210-bib-0154"><mixed-citation publication-type="journal" id="pcmr13210-cit-0154">
<string-name>
<surname>Zhou</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Chen</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature</article-title>.&#x0201d; <source>Frontiers in Cell and Development Biology</source>
<volume>9</volume>: <elocation-id>739594</elocation-id>. <pub-id pub-id-type="doi">10.3389/fcell.2021.739594</pub-id>.</mixed-citation></ref><ref id="pcmr13210-bib-0155"><mixed-citation publication-type="journal" id="pcmr13210-cit-0155">
<string-name>
<surname>Zocchi</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Lontano</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Merli</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management</article-title>.&#x0201d; <source>Journal of Clinical Medicine</source>
<volume>10</volume>: 3760. <pub-id pub-id-type="doi">10.3390/jcm10163760</pub-id>.</mixed-citation></ref></ref-list></back></article>